Document:

EX-10.2

 Exhibit 10.2 

EXECUTIVE EMPLOYMENT AGREEMENT 

BETWEEN 
 VAALCO ENERGY,
INC. 
 AND 

GEORGE MAXWELL 

(EFFECTIVE AS OF APRIL 19, 2021) 

 TABLE OF CONTENTS 

 

							
	 Article 1. EMPLOYMENT AND DUTIES
	  	 	1	 
			
	 1.1
	 	Definitions	  	 	1	 
	 1.2
	 	Employment; Effective Date	  	 	1	 
	 1.3
	 	Positions	  	 	1	 
	 1.4
	 	Duties and Services	  	 	2	 
	 1.5
	 	Other Interests	  	 	3	 
	 1.6
	 	Duty of Loyalty	  	 	3	 
	 1.7
	 	Executive Warranties	  	 	3	 
		
	 Article 2. TERM AND TERMINATION OF EMPLOYMENT
	  	 	4	 
			
	 2.1
	 	Term of Employment	  	 	4	 
	 2.2
	 	Notice of Termination	  	 	4	 
	 2.3
	 	Resignation of Offices	  	 	4	 
	 2.4
	 	Summary Termination (for Cause)	  	 	4	 
		
	 Article 3. COMPENSATION AND BENEFITS
	  	 	5	 
			
	 3.1
	 	Base Salary	  	 	5	 
	 3.2
	 	Annual Bonuses	  	 	5	 
	 3.3
	 	Equity Awards after the Effective Date	  	 	5	 
	 3.4
	 	Business and Entertainment Expenses	  	 	5	 
	 3.5
	 	Vacation	  	 	5	 
	 3.6
	 	Health Benefits	  	 	6	 
	 3.7
	 	Pension Benefits	  	 	6	 
	 3.8
	 	Incapacity	  	 	6	 
	 3.9
	 	Other Paid Leave	  	 	7	 
	 3.10
	 	Training	  	 	7	 
	 3.11
	 	Disciplinary & Grievance Procedures	  	 	7	 
		
	 Article 4. RIGHTS AND PAYMENTS UPON TERMINATION
	  	 	8	 
			
	 4.1
	 	Rights and Payments upon Termination	  	 	8	 
	 4.2
	 	Limitation on Other Severance Benefits	  	 	9	 
	 4.3
	 	Settlement Agreement	  	 	10	 
	 4.4
	 	Notice of Termination	  	 	10	 
	 4.5
	 	Payment in Lieu of Notice	  	 	11	 
	 4.6
	 	Garden Leave	  	 	11	 
		
	 Article 5. CONFIDENTIAL INFORMATION AND RESTRICTIVE COVENANTS
	  	 	12	 
			
	 5.1
	 	Access to Confidential Information and Specialized Training	  	 	12	 
	 5.2
	 	Agreement Not to Use or Disclose Confidential Information	  	 	12	 
	 5.3
	 	Duty to Return Company Documents and Property	  	 	13	 
	 5.4
	 	Intellectual Property	  	 	14	 

  
 i 

							
	 5.5
	 	Inventions	  	 	14	 
	 5.6
	 	Post Termination Restrictions	  	 	15	 
	 5.7
	 	Forfeiture of Severance Payment	  	 	17	 
	 5.8
	 	Removal of Restrictions by Court	  	 	18	 
	 5.9
	 	No Previous Restrictive Agreements	  	 	18	 
	 5.10
	 	Conflicts of Interest	  	 	18	 
	 5.11
	 	Remedies	  	 	18	 
	 5.12
	 	No Disparaging Comments	  	 	19	 
	 5.13
	 	Company Documents and Property	  	 	19	 
	 5.14
	 	Data Protection	  	 	19	 
	 5.15
	 	Collective Agreements	  	 	19	 
		
	 Article 6. GENERAL PROVISIONS
	  	 	20	 
			
	 6.1
	 	Matters Relating to Section 409A of the Code	  	 	20	 
	 6.2
	 	Withholdings; Right of Deduction	  	 	20	 
	 6.3
	 	Nonalienation	  	 	20	 
	 6.4
	 	Incompetent or Minor Payees	  	 	20	 
	 6.5
	 	Indemnification	  	 	20	 
	 6.6
	 	Successors and Assigns	  	 	21	 
	 6.7
	 	Notice	  	 	21	 
	 6.8
	 	Severability	  	 	22	 
	 6.9
	 	No Third Party Beneficiaries	  	 	22	 
	 6.10
	 	Waiver of Breach	  	 	22	 
	 6.11
	 	Survival of Certain Provisions	  	 	22	 
	 6.12
	 	Entire Agreement; Amendment and Termination	  	 	22	 
	 6.13
	 	Interpretive Matters	  	 	22	 
	 6.14
	 	Governing Law; Jurisdiction	  	 	23	 
	 6.15
	 	Executive Acknowledgment	  	 	23	 
	 6.16
	 	Counterparts	  	 	23	 

  

					
	 Appendix A
	  	 	A-1	 
		
	 Appendix B
	  	 	B-1	 

  

  
 ii 

 EXECUTIVE EMPLOYMENT AGREEMENT 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), shall be effective as of April 19, 2021 (the “Effective
Date”) and is made and entered into by and between VAALCO Energy, Inc., a Delaware corporation (hereafter “Company”) and George Maxwell (hereafter “Executive”). The Company and Executive may
sometimes hereafter be referred to singularly as a “Party” or collectively as the “Parties.” The addresses of the Parties are set forth in the Notice section of this Agreement. 

W I T N E S S E T H: 

WHEREAS, the Company desires to secure the employment services of Executive subject to the terms and conditions hereafter set forth; and

 WHEREAS, Executive is willing to enter into this Agreement upon the terms and conditions hereafter set forth; 

NOW, THEREFORE, in consideration of Executive’s employment with the Company, and the mutual promises, covenants and obligations
contained herein, the Parties hereby agree as follows: 
 Article 1. 

EMPLOYMENT AND DUTIES 

1.1 Definitions. In addition to the terms defined in the text hereof, terms with initial capital letters as used herein
have the meanings assigned to them, for all purposes of this Agreement, in the Definitions Appendix hereto, unless the context reasonably requires a broader, narrower or different meaning. The Definitions Appendix, as attached hereto, is part of
this Agreement and incorporated herein. 
 1.2 Employment; Effective Date. The Executive’s employment under this
Agreement shall commence as of the Effective Date and continue for the Employment Period (as defined in Section 2.1). Executive has no previous period of continuous employment with Company. The Executive’s employment
by the Company shall be subject to the terms and conditions of this Agreement. No probationary period applies to the employment of Executive. 

1.3 Positions. As of the Effective Date, the Executive will serve as the Chief Executive Officer of the Company
(“CEO”) and, in due course, as required by the Company, CEO of any such directly or indirectly fully-owned subsidiary of the Company that is domiciled in the United Kingdom (and to which this agreement may be assigned or transferred
pursuant to Section 6.6 below) and Executive hereby consents to such assignment or transfer of his employment. In addition, Executive shall serve as a member of the Board of Directors of the Company (the “Board of Directors”).
Subject to the terms and conditions of this Agreement, Executive shall serve in the position of CEO and/or in such other position or positions as the Parties may mutually agree, during the Employment Period. In addition, the Company shall nominate
the Executive for re-election to the Board of Directors as and when his term expires during the Employment Period, 

  
 1 

 
unless otherwise determined by the Board of Directors. If the Executive is not nominated for re-election then the last day of his membership of the Board
shall be his Termination Date, and the Executive shall be entitled to the rights and payments pursuant to Article 4 to which he is then entitled subject to any conditions applying to such payments, and in particular if the failure to nominate
the Executive for re-election was due to Cause (as defined in Section 2.4) then the Executive will only be entitled to the payments in Section 2.4 

1.4 Duties and Services. The Executive agrees to serve in the positions referred to in
Section 1.3 and to perform diligently and faithfully to the best of his abilities the duties and services appertaining to such offices, as well as such additional duties and services appropriate to such offices upon which
the Parties mutually may agree from time to time or that are assigned to him by the Board of Directors. The Executive’s employment shall also be subject to the policies maintained and established by the Company from time to time, as the same
may be amended or otherwise modified. 
 Executive shall at all times use his best efforts to in good faith comply with English, United
States and foreign laws applicable to Executive’s actions on behalf of the Company and its Affiliates. Executive’s normal place of work is in such place in London, UK as may be specified as Company offices (from time to time) or such other
place where the Board of Directors may reasonably require for the proper exercise and performance of his duties. Executive understands and agrees that he may be required to travel extensively at times for purposes of the Company’s business
including, but not limited to, travel to the Company’s corporate offices in the Houston, Texas, metropolitan area, from time to time, upon request by the Board of Directors or according to the needs to the business. This may include working
outside of the UK for a period or periods in excess of one month. 
 Executive’s normal working hours shall be from 9:00 a.m. to 6:00
p.m. GMT on Mondays through Fridays. These hours and days are not variable, although Executive may be required to work such additional hours as are necessary for the proper performance of his duties. Executive acknowledges that he shall not receive
additional remuneration in respect of such additional hours. The Parties each agree that the nature of Executive’s position is such that his working time cannot be measured and, accordingly, that his employment falls within the scope of
regulation 20 of the UK Working Time Regulations 1998 (SI 1998/1833). 
 The Company takes a
zero-tolerance approach to tax evasion. Executive must not engage in any form of facilitating tax evasion, whether under UK law or under the law of any foreign country. Executive must immediately report to the
Board of Directors any request or demand from a third party to facilitate the evasion of tax or any concerns that such a request or demand may have been made. Executive must at all times comply with the Company’s “Anti-Bribery and Anti-Tax Avoidance Compliance Policy”, a copy of which is available from the Company’s General Counsel (the “General Counsel”) and which may be updated from time to time. 

The Company confirms that the Executive will not be required to invest more than three times his Base Salary in the stock of the Company, over
the five-year period from the Effective Date, irrespective of any other policy or practice in effect at the Company from time to time. 

  
 2 

 1.5 Other Interests. The Executive agrees that, during the Employment
Period, unless prevented by Incapacity, he will devote his whole time and attention, energy and best efforts to the business and affairs of the Company and its Affiliates, and not to engage, directly or indirectly, in any other business or
businesses, whether or not similar to that of the Company or an Affiliate, except with the consent of the Board of Directors. The foregoing notwithstanding, the Parties recognize and agree that the Executive may engage in passive personal
investments (such as real estate investments and rental properties) and other civic and charitable activities (such as continued service on non-profit and/or educational boards) that do not conflict with the
business and affairs of the Company or interfere with the Executive’s performance of his duties hereunder without the necessity of obtaining the consent of the Board of Directors; provided, however, Executive agrees that if the Compensation
Committee of the Board of Directors (the “Compensation Committee”) determines that continued service with one or more civic or charitable entities is inconsistent with the Executive’s duties hereunder and gives written notice
to the Executive, he will promptly resign from such position(s). This Section 1.5 shall not apply to any interests with which the Executive is currently engaged and which have previously been disclosed to, and approved by, the Chairman of the
Board of Directors, prior to the Effective Date. This Agreement shall not apply to restrict or curtail the Executive’s current level of involvement in such disclosed interests provided that, in respect of such interests, priority and precedence
shall always be given to Executive’s duties for the Company under this Agreement. 
 1.6 Duty of Loyalty. The
Executive acknowledges and agrees that the Executive owes a fiduciary duty of loyalty, fidelity, and allegiance to use his best endeavours to act at all times in the best interests of the Company and its Affiliates. In keeping with these duties, the
Executive shall make full disclosure to the Company of all business opportunities pertaining to the Company’s business, and he shall not appropriate for the Executive’s own benefit any business opportunity concerning the subject matter of
such fiduciary relationship. Executive shall comply with any statutory, fiduciary or common law duties to the Company, of which he is a director and not take any action which would cause him to be disqualified from acting as a director. He shall use
his best endeavours to promote, protect, develop and extend the Company business and comply with all reasonable and lawful directions given to him by the Board of Directors and promptly make such reports to the Board of Directors in connection with
the Company’s business or affairs on such matters or at such times as are reasonably required. 
 1.7 Executive
Warranties. The Executive represents and warrants to the Company that, by entering into this agreement or performing any of his obligations under it, he will not be in breach of any court order or any express or implied terms of any contract
or other obligation binding on him. The Executive warrants that he is entitled to work in the UK without any additional approvals and will notify the Company immediately if he ceases to be so entitled during the Employment Period. The Executive
warrants that he is not subject to any restrictions which prevent him from holding office as a director. 

  
 3 

 Article 2. 

TERM AND TERMINATION OF EMPLOYMENT 

2.1 Term of Employment. Unless sooner terminated pursuant to other provisions hereof, the Company agrees to employ the
Executive for the period beginning on the Effective Date and ending on April 30, 2022 (the “Initial Term of Employment”). Beginning effective as of May 1, 2022 (the “Initial Extension Date”), the term of
employment hereunder shall be extended automatically for an additional successive one-year period as of such date and as of each annual anniversary of the Initial Extension Date that occurs while this
Agreement remains in effect so that the remaining term is one year; provided, however, if, at any time prior to the date that is at least twenty-eight (28) days (subject to statutory minimum as per Notice of Termination in
Section 2.2) before the Initial Extension Date or any annual anniversary thereof, either Party gives Notice of Termination to the other Party that no such automatic extension shall occur and the Executive’s employment
shall terminate on April 30 of the then-current one-year extension, then, for purposes of clarity, such termination shall not be a Severance Payment Event. 

The Initial Term of Employment, and any extension of employment hereunder, shall be referred to herein as a “Term of
Employment.” The entire period from the Effective Date through the date of Executive’s termination of employment with the Company, for whatever reason, shall be referred to herein as the “Employment Period.” 

2.2 Notice of Termination. If the Company or the Executive desires to terminate the Executive’s employment hereunder
at any time as of, or prior to, expiration of the Term of Employment, with or without Cause, such Party shall do so by giving written “Notice of Termination” to the other Party, subject to the terms and conditions of this Agreement
regarding the rights and duties of the Parties upon termination of employment, and provided, however, that no such action shall alter or amend any other provisions hereof or rights arising hereunder. No further renewals of the Term of Employment
hereunder shall occur pursuant to Section 2.1 after the giving of such Notice of Termination. 
 Such Notice of
Termination by either Party shall be provided with at least four weeks’ notice. This minimum notice period shall increase by one week per year of employment after four years of continuous employment up to a maximum of 12 weeks’ notice
after 12 years of continuous employment. 
 2.3 Resignation of Offices. Notwithstanding any other provision of this
Agreement, upon the termination of the Executive’s employment hereunder for any reason, unless otherwise requested by the Compensation Committee, Executive shall immediately resign from the Board of Directors and from all officer positions and
all boards of directors of any Affiliates of which he may be a member. The Executive hereby agrees to execute any and all documentation of such resignations upon request by the Company, but he shall be treated for all purposes as having so resigned
his officeholdings upon termination of his employment, regardless of when or whether he executes any such documentation. 
 2.4
Summary Termination (for Cause). The Company may terminate the employment of Executive with immediate effect without notice and with no liability to make any further payment to him (other than in respect of amounts accrued due at the
date of termination) if Cause (as defined herein) has occurred or exists to terminate Executive and the Board of Directors have determined that to be the case. 

The Company’s rights under this Section are without prejudice to any other rights that the Company might have at law to terminate the
employment of Executive or to accept any breach of this Agreement by him as having brought the Agreement to an end. Any delay by the Company in exercising its rights to terminate shall not constitute a waiver of these rights. 

  
 4 

 Article 3. 

COMPENSATION AND BENEFITS 

3.1 Base Salary(a) . During the Employment Period, the Executive shall receive a minimum annual base salary of US$450,000,
which shall be prorated for any period of less than 12 months (the “Base Salary”). The Compensation Committee shall review the Executive’s Base Salary on an annual basis and may, in its sole discretion, increase, but not
decrease, the Base Salary, and references in this Agreement to “Base Salary” shall refer to annual Base Salary as so increased. The Base Salary shall accrue daily and be paid in equal installments in accordance with the Company’s
standard policy regarding payment of compensation to executives, but no less frequently than monthly and shall be subject to such deductions as the Company is required by law to make. The Executive will be paid through the Company’s U.S.
payroll in USD, unless and until the Parties agree otherwise. 
 3.2 Annual Bonuses. For the 2021 calendar year and
subsequent calendar years during the Employment Period, the Executive shall be eligible to receive an annual cash bonus (the “Annual Bonus”) under the Company’s annual incentive cash bonus plan for executives or any successor
incentive cash bonus plan (the “Bonus Plan”), in an amount to be determined by the Compensation Committee, based on performance goals established by the Compensation Committee, in its discretion, pursuant to the terms of the Bonus
Plan, and with a target percentage (the “Incentive Target Percentage”) of fifty percent (50%) of the Executive’s annual Base Salary as in effect at the beginning of the calendar year and may scale up or down based on
achievement of personal and corporate goals established by the Compensation Committee. 
 3.3 Equity Awards after the Effective
Date. During the Employment Period on and after the Effective Date, the Executive shall be eligible for stock options or other incentive awards in accordance with normal competitive pay practices, on a basis no less favorable than the
process and approach used for the Company’s other senior executives, as determined by the Compensation Committee in its discretion. The annual long-term incentive award shall be up to fifty percent (50%) of Executive’s Base Salary. 

3.4 Business and Entertainment Expenses. Subject to the Company’s standard policies and procedures with respect to
expense reimbursement as applied to its executives generally, the Company shall reimburse the Executive for, or pay on behalf of the Executive, the reasonable and appropriate expenses incurred by the Executive for business related purposes,
including dues and fees to industry and professional organizations and costs of entertainment and business development. 
 3.5
Vacation. The Company’s “Holiday Year” is a calendar year. The Executive shall be entitled to 25 days of paid vacation, plus public and bank holidays in England and Wales, each Holiday Year in accordance with the
Company’s vacation policy, as in effect from time to time. Such vacation leave entitlement in the first and last years of Executive’s employment shall be pro-rated accordingly. Executive shall not
carry forward any accrued but untaken paid vacation entitlement to a subsequent Holiday Year unless he has been prevented from taking it in the 

  
 5 

 
relevant Holiday Year by one of the following: a period of sickness absence or statutory maternity, paternity, adoption, shared parental, parental or parental bereavement leave. In cases of
sickness absence, carry-over is limited to four weeks’ vacation leave per Holiday Year less any leave taken during the Holiday Year that has just ended. Any such carried over vacation leave which is not taken within 6 months of the end of the
relevant Holiday Year will be lost and forfeited. The Company shall not pay the Executive in lieu of untaken vacation leave except on termination of his employment. On termination of employment, the Company shall pay Executive in lieu of any accrued
but untaken vacation leave for the Holiday Year in which termination takes place and any untaken days permitted to be carried forward from the preceding Holiday Year. The amount of the payment in lieu of accrued vacation time will be calculated as
1/260th of Base Salary for each untaken day of the entitlement. Executive Benefits. 
 3.6 Health Benefits. During each
calendar year of the Employment Period, beginning on the Effective Date and pro-rated in the first and last calendar years of the Employment Period, as necessary, the Company shall pay to Executive an annual
amount of US$22,000, which amount shall be indexed annually, effective as of January 1 for each calendar year during the Employment Period, based on the UK Consumer Prices Index (CPI), as an allowance for him to enable his participation in
health and welfare benefits, including the acquisition of private health insurance as he may elect in his discretion. 
 3.7
Pension Benefits. During each calendar year of the Employment Period, beginning on the Effective Date and pro-rated in the first and last calendar years of the Employment Period, as necessary,
the Company shall pay to Executive an annual amount of US$17,000, which amount shall be indexed annually, effective as of January 1 for each calendar year during the Employment Period, based on the UK Consumer Prices Index (CPI), as an
allowance for him to invest in either a personal pension scheme or similar retirement funding as he may elect in his discretion. 

3.8 Incapacity. If the Executive is absent from work due to Incapacity, he (or a person on his behalf) shall notify the
Board of Directors of the reason for the absence as soon as possible but no later than 10:00 a.m. on the first day of absence. Subject to the Executive’s compliance with this agreement and the Company’s “Medical Sick Leave
Policy” and “Extended Medical Leave Policy” Executive shall be entitled to receive his full Base Salary during any periods of sickness absence up to a maximum of two weeks in any 52-week period.
This does not affect any entitlement Executive may have to receive Statutory Sick Pay (“SSP”) for the same periods of sickness absence, although any sick pay Executive receives from the Company shall be inclusive of any SSP due to
him. Executive’s qualifying days for SSP purposes are Monday to Friday. 
 Executive agrees to consent to medical examinations (at the
Company’s expense) by a doctor nominated by the Company at any time should we so require. If the Incapacity is or appears to be occasioned by actionable negligence, nuisance or breach of any statutory duty on the part of a third party in
respect of which damages are or may be recoverable, Executive shall immediately notify the Board of Directors of that fact and of any claim, settlement or judgment made or awarded in connection with it and all relevant particulars that the Board of
Directors may reasonably require. Executive shall if required by the Board of Directors, co-operate in any related legal proceedings and refund to the Company that part of any damages or compensation recovered
by Executive relating to the loss of earnings for the period of the Incapacity, as the Board of Directors may reasonably determine, less any costs borne by Executive in connection with the recovery of

  
 6 

 
such damages or compensation, provided that the amount to be refunded shall not exceed the total amount paid to Executive by the Company in respect of the period of Incapacity. The Company’s
rights to terminate this employment of Executive under the terms of this agreement apply even when such termination would or might cause Executive to forfeit any entitlement to sick pay or other benefits. 

3.9 Other Paid Leave . Executive may be eligible to take the following types of paid leave, subject to any
statutory eligibility requirements or conditions (and the Company’s rules) applicable to each type of leave in force from time to time: statutory paternity leave; statutory adoption leave; shared parental leave; and parental bereavement leave.
Further details of such leave and any pay during such leave are available from the General Counsel. 
 3.10 Training.
Aside from the Specialized Training, no training will be provided to Executive during the Employment Period 
 3.11
Disciplinary & Grievance Procedures. Executive shall be subject to the Company’s “Employee Handbook” and “Code of Business Conduct and Ethics”, copies of which
are available upon request by Executive from the General Counsel. Executive may also request a copy of the grievance and disciplinary procedures for Executive from the General Counsel. These rules and procedures do not form part of Executive’s
contract of employment. 
 If Executive wishes to appeal against a grievance decision he may do so in writing to the Board of Directors in
accordance with Company procedure as set out in the grievance procedure for Executive. If Executive wishes to appeal against a disciplinary decision he may apply in writing to the Board of Directors in accordance with Company disciplinary procedure.

 The Board of Directors may suspend Executive from any or all of his duties for no longer than is necessary to investigate any disciplinary
matter involving him or so long as is otherwise reasonable while any disciplinary procedure against you is outstanding. During any period of suspension: 

(a) Executive shall continue to receive his Base Salary and all contractual benefits in the usual way and subject to the terms
of any benefit arrangement; 
 (b) Executive shall remain an employee and bound by the terms of this Agreement; 

(c) Executive shall ensure that the Board of Directors knows where he will be and how he can be contacted during each working
day (except during any periods taken as holiday in the usual way); 
 (d) the Board of Directors may exclude Executive from
his place of work or any of the Company’s or its Affiliate’s other premises; and 
 (e) the Board of Directors may
require Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee, consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of the Company or any Affiliate 

  
 7 

 Article 4. 

RIGHTS AND PAYMENTS UPON TERMINATION. 

4.1 Rights and Payments upon Termination. Executive’s right to compensation and benefits for periods after the date
on which his employment terminates with the Company and all Affiliates (the “Termination Date”) shall be determined in accordance with this Article 4, as follows: 

(a) Minimum Payments. Executive shall be entitled to the following minimum payments under this
Section 4.1(a), in addition to any other payments or benefits to which he is entitled to receive under the terms of this Agreement or any employee benefit plan or program: 

(i) his accrued and unpaid Base Salary through the Termination Date; 

(ii) his accrued and unused vacation days through the Termination Date; 

(iii) reimbursement of his reasonable business expenses that were incurred but unpaid as of the Termination Date; and 

(iv) if the Executive is not required to work and has given or been given Notice of Termination, payment of Base Salary in lieu
of notice pursuant to Sections 2.2 and 4.5. 
 Such salary, payment in lieu of notice (if applicable) and
accrued vacation days shall be paid to Executive within five (5) Business Days following the Termination Date in a cash lump sum less applicable withholdings and any tax or National Insurance Contributions which the Company is required by law
to deduct. Business expenses shall be reimbursed in accordance with the Company’s normal policy and procedures. 
 (b)
Termination Benefits. In the event that during the Term of Employment Executive incurs a Severance Payment Event, the following severance benefits shall be provided to Executive hereunder or, in the event of his death before receiving
all such benefits, to his Designated Beneficiary following his death: 
 (i) Additional Payment. The Company shall pay
to Executive as additional compensation (the “Additional Payment”), an amount equal to fifty percent (50%) (in the event of a Regular Severance Payment Event), or one hundred fifty percent (150%) (in the event of a CIC Severance
Payment Event), multiplied by the aggregate sum of the following compensation items: 
 (A) Executive’s Base Salary as
in effect as of the Termination Date; plus 

  
 8 

 (B) an amount equal to the greater of (i) the average of
Executive’s Annual Bonus (or other cash incentive bonus) paid or payable to Executive by the Company for the two calendar years immediately preceding the calendar year in which the Termination Date occurs or (ii) Executive’s target Annual
Bonus for the full calendar year in which the Termination Date occurs; provided, however, in the event that the Termination Date occurs before the end of the calendar year, Executive shall be entitled to a prorata portion of the greater of clause
(i) or (ii) above (based on the number of days in which he was employed during that year divided by 365). 

Regardless of whether attributable to a Regular Severance Payment Event or a CIC Severance Payment Event, and subject to
Section 4.1(b)(ii) in the event of an Anticipatory Termination, the Company shall make the Additional Payment to Executive over a six (6) month period in twelve (12) substantially equal bi-monthly payments that begin within twenty (20) days following the Termination Date. The payment of any Additional Payment shall be made in accordance with, and subject to, the Release requirements of
Section 4.3 and the Company’s standard payroll procedures. In the event of Executive’s death prior to the payment of all installments of the (1) Additional Payment as provided above, or (2) the Remaining
Additional Payment Amount as provided in Section 4.1(b)(ii), the remaining installment payments shall be aggregated and paid in a single sum payment to the Executive’s Designated Beneficiary within sixty (60) days
from Executive’s date of death. 
 (ii) Anticipatory Termination. Notwithstanding any provision of this
Agreement to the contrary, in the event of an Anticipatory Termination, the Company shall compute the Additional Payment payable to Executive as the result of a CIC Severance Payment Event and offset from such amount the aggregate amount of the
installments of the Additional Payment, if any, that were already paid to Executive through the Change in Control Date as the result of his Regular Severance Payment Event. This Additional Payment attributable to the Executive’s CIC Severance
Payment Event, as offset by any installment payments already made to Executive in respect of a Regular Severance Payment Event through the Change in Control Date, is defined as the “Remaining Additional Payment Amount”. The
Remaining Additional Payment Amount shall be paid to Executive in substantially equal, bi-monthly installment payments over the remaining term of the one-year period
that is specified in Section 4.1(b)(i). The Remaining Additional Payment Amount shall be paid to Executive, as provided above, without the requirement that Executive enter into a new Release Agreement. 

4.2 Limitation on Other Severance Benefits. 

(a) Limitation on Other Severance Payments. For purposes of clarity, in the event that (i) Executive voluntarily
resigns or otherwise voluntarily terminates his own employment during the Term of Employment, except for (A) Good Reason or (B) due to his death or Disability, or (ii) Executive’s employment is terminated due to a No
Severance Benefits Event, then, in either such event under clause (i) or (ii), the Company shall have no obligation to provide the severance benefits described in subsections (i) and (ii) of
Section 4.1(b), Executive shall still be entitled to receive the severance benefits provided under Section 4.1(a). 

  
 9 

 (b) No Duplication of Severance Benefits. Notwithstanding
Section 4.1, if Executive receives or is entitled to receive any severance benefit under any change of control policy, or any agreement with, or plan or policy of, the Company or any Affiliate, the amount payable under
Section 4.1(b) to or on behalf of Executive shall be offset by such other severance benefits received by Executive, and Executive shall thus be entitled to receive the greater of such other severance benefits or the
benefits provided under this Agreement, and not any duplicate benefits. The severance payments provided under this Agreement shall also supersede and replace any duplicative severance benefits under any severance pay plan or program that the Company
or any Affiliate maintains for employees generally and that otherwise may cover Executive. 
  

4.3 Settlement Agreement. In order to receive the Termination Benefits, Executive must first execute a standard form
Settlement Agreement in substantially the same form as the template document provided by the Company and which is appended to this Agreement as Appendix B. The Executive shall retain a Legal Adviser (as defined in the Settlement Agreement),
as the Legal Adviser is also required to execute the Settlement Agreement. The Settlement Agreement will be modified as deemed to be necessary or appropriate to the circumstances of the Executive’s termination and delivered to the Executive
within fifteen (15) Business Days of the Termination Date, failing which the Company will be deemed to have waived any requirement for the Executive to sign a Settlement Agreement. Pursuant to the Settlement Agreement, Executive shall agree to
release and waive, in return for such severance benefits, any employment-related claims or those claims related to his termination that he may have against the Company provided, however, the Settlement Agreement shall not waive any claim by or on
behalf of Executive for any payment or benefit that is due and payable under the terms of this Agreement prior to the receipt thereof, and it shall not prevent the Executive enforcing the terms of the Settlement Agreement once agreed, or from
relying on the provisions of any post termination rights (including, but without limitation, Section 6.5 below,) given to the Executive under this Agreement. The Executive must return the executed Settlement Agreement
within fifteen (15) Business Days following the date of his receipt of that document (the “Settlement Period”) to receive Termination Benefits. If the Executive, and his Legal Adviser (as defined in the Settlement Agreement),
signs and returns the executed Settlement Agreement within the Settlement Period, then the Executive shall be entitled to the Termination Benefits irrespective of whether the Company signs the Settlement Agreement. 

If the Settlement Agreement delivery and non-revocation period spans two taxable years, the
Termination Benefits will always be paid in the second taxable year. No Termination Benefits shall be payable or provided by the Company unless and until the Settlement Agreement has been fully executed by Executive and his Legal Adviser (as defined
therein), if any, has not been revoked, and is no longer subject to revocation by Executive, and the Termination Benefits will be paid 30 days thereafter the last applicable event. 

4.4 Notice of Termination. Any termination of employment by the Company or Executive shall be communicated by Notice of
Termination, pursuant to Section 2.2, to the other Party. 

  
 10 

 4.5 Payment in Lieu of Notice Notwithstanding the other provisions in
this Section 4, the Company may, in its sole and absolute discretion, terminate the Employment Period at any time and with immediate effect by notifying Executive that it is exercising its right under this section and that
it will make, within 28 days, a payment in lieu of notice (the “Payment in Lieu”) to Executive. The Payment in Lieu will be equal to Executive’s Base Salary (as at the Termination Date) which he would have been entitled to
receive under this agreement during the notice period referred to in Section 2.2 (or, if Notice of Termination has already been given, during the remainder of the notice period), less the usual income tax and National
Insurance contributions. For the avoidance of doubt, the Payment in Lieu shall not include any element in relation to: 
 (a)
any bonus or commission payments that might otherwise have been due during the period for which the Payment in Lieu is made; 

(b) any payment in respect of benefits which Executive would have been entitled to receive during the period for which the
Payment in Lieu is made; and 
 (c) any payment in respect of any holiday entitlement that would have accrued during the
period for which the Payment in Lieu is made. 
 The Company may choose to pay any sums due under this Section 4.5
in equal monthly installments until the date on which the notice period would have expired if notice had been given. 
 Executive shall have
no right to receive a Payment in Lieu unless the Company has exercised its discretion in relation to this Section and nothing in this Section shall prevent the Company from terminating Executive’s employment in breach. Notwithstanding this
Section Executive shall not be entitled to any Payment in Lieu if the Company would otherwise have been entitled to terminate the Employment Period without notice on the basis of a For Cause termination. In that case the Company shall also be
entitled to recover from Executive any Payment in Lieu (or any installments) already made. 
 4.6 Garden Leave.
Following service of notice to terminate the Employment Period by either Party, or if Executive purports to terminate his employment under this Agreement in breach of contract, the Board of Directors may by written notice place Executive on Garden
Leave for the whole or part of the remainder of the Executive’s Notice Period. During any period of Garden Leave: 
 (a)
Executive shall not be a director of the Company unless the Board of Directors determines otherwise; 
 (b) the Company shall
be under no obligation to provide any work to Executive and may revoke any powers he holds on any Company or Affiliate’s behalf; 

(c) the Company may require Executive to carry out alternative duties or to only perform such specific duties as are expressly
assigned to him, at such location (including home) as the Company may decide; 
 (d) Executive shall continue to receive his
Base Salary and all contractual benefits in the usual way and subject to the terms of any benefit arrangement; 

  
 11 

 (e) Executive shall remain an employee and bound by the terms of this
Agreement (including any implied duties of good faith and fidelity); 
 (f) Executive shall ensure that the Board of
Directors knows where he will be and how he can be contacted during each working day (except during any periods taken as holiday in the usual way); 

(g) the Company may exclude Executive from any of the Company’s or Affiliate’s premises; and 

(h) the Company may require Executive not to contact or deal with (or attempt to contact or deal with) any officer, employee,
consultant, client, customer, supplier, agent, distributor, shareholder, adviser or other business contact of the Company or any Affiliate. 

Article 5. 
 CONFIDENTIAL
INFORMATION AND 
 RESTRICTIVE COVENANTS 

5.1 Access to Confidential Information and Specialized Training. In connection with his employment and continuing on an
ongoing basis during the Employment Period, the Company and its Affiliates will give Executive access to Confidential Information, which Executive did not have access to or knowledge of before the execution of this Agreement. Executive acknowledges
and agrees that all Confidential Information is confidential and a valuable, special and unique asset of the Company that gives the Company an advantage over its actual and potential, current and future competitors. Executive further acknowledges
and agrees that Executive owes the Company a fiduciary duty to preserve and protect all Confidential Information from unauthorized disclosure or unauthorized use, that certain Confidential Information constitutes “trade secrets” under
applicable laws, and that unauthorized disclosure or unauthorized use of the Confidential Information would irreparably injure the Company or any of its Affiliates. 

The Company also agrees to provide Executive with Specialized Training, which Executive does not have access to or knowledge of before the
execution of this Agreement and continuing on an ongoing basis during his employment. 
 5.2 Agreement Not to Use or Disclose
Confidential Information. Both during the term of Executive’s employment and after his termination of employment for any reason (including wrongful termination), Executive shall hold all Confidential Information in strict confidence,
and shall not use any Confidential Information except for the benefit of the Company or its Affiliates, in accordance with the duties assigned to Executive. Executive shall not, at any time (either during or after the term of Executive’s
employment), disclose any Confidential Information to any Person (except other Persons who have a need to know the information in connection with the performance of services for the Company or its Affiliate), or copy, reproduce, modify, decompile or
reverse engineer any Confidential Information, or remove any Confidential Information from the Company’s premises, without the prior written consent of the Compensation Committee, or permit any other Person to do so. Executive shall take
reasonable precautions to protect the physical security of all documents and other material containing Confidential Information (regardless of the medium on which the Confidential Information is stored). This agreement and covenant applies to all
Confidential Information, whether now known or later to become known to Executive. 

  
 12 

 The Executive shall hold in a fiduciary capacity for the benefit of the Company all
Confidential Information relating to the Company or any of its Affiliates, and their respective businesses, that has been obtained by the Executive during the Executive’s employment by the Company and which is not public knowledge (other than
by acts of the Executive or representatives of the Executive in violation of this Agreement). 
 Following the termination of the
Executive’s employment with the Company for any reason, the Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, or in compliance with any legal regulatory or compliance
obligation or process, communicate or divulge any such Confidential Information to any Person other than the Company and those designated by it. This Section shall not apply to any information which is already in, or comes into, the public domain
other than through Executive’s unauthorised disclosure; or any protected disclosure within the meaning of section 43A of the Employment Rights Act 1996. 

The Company has and will disclose to the Executive, or place the Executive in a position to have access to or develop, trade secrets and
Confidential Information of the Company or its Affiliates; and/or has and will place the Executive in a position to develop business goodwill on behalf of the Company or its Affiliates; and/or has and will entrust the Executive with business
opportunities of the Company or its Affiliates. As part of the consideration for the compensation and benefits to be paid to the Executive hereunder; the Executive hereby agrees to accept these restrictions in this Section to protect the trade
secrets and Confidential Information of the Company and its Affiliates that have been and will in the future be disclosed or entrusted to the Executive, the business goodwill of the Company and its Affiliates that has been and will in the future be
developed in the Executive, or the business opportunities that have been and will in the future be disclosed or entrusted to the Executive; and as an additional incentive for the Company to enter into this Agreement, the Company and the Executive
agree to the non-competition and the non-solicitation obligations set forth in this Agreement. 

5.3 Duty to Return Company Documents and Property. Upon the termination of Executive’s employment with the Company
and its Affiliates, for whatever reason, or upon the request of the Board of Directors at any time, Executive shall immediately return and deliver to the Company any and all papers, books, records, documents, memoranda and manuals, e-mail, electronic or magnetic recordings or data, including all copies thereof, belonging to the Company or its Affiliate or relating to their businesses, in Executive’s possession or under his control, and
regardless of, whether prepared by Executive or others. If at any time after the Employment Period, Executive determines that he has any Confidential Information in his possession or under his control, Executive shall immediately return to the
Company all such Confidential Information, including all copies (including electronic versions) and portions thereof. Executive. will, at the Company’s request, provide without delay a written and signed confirmation of compliance with this
Section. 

  
 13 

 Within one (1) day after the end of the Employment Period for any reason, the Executive
shall return to Company all Confidential Information which is in his possession, custody or control. 
 5.4
Intellectual Property. Executive shall promptly disclose to the Company all ideas, inventions, computer programs, and discoveries, whether or not patentable or copyrightable, which he may conceive or make, alone or with
others, during the Employment Period, whether or not during working hours, and which directly or indirectly: 
 (a) relate to
matters within the scope, field, duties or responsibility of Executive’s employment with the Company; or 
 (b) are
based on any knowledge of the actual or anticipated business or interest of the Company or any of its Affiliates; or 
 (c)
are aided by the use of time, materials, facilities or information of the Company or its Affiliate. 
 Executive shall assign to the
Company, without further compensation, all rights, titles and interest in all such ideas, inventions, computer programs and discoveries in all countries of the world. 

Executive recognizes that all ideas, inventions, computer programs and discoveries of the type described above, conceived or made by Executive
alone or with others within six (6) months after termination of employment (voluntary or otherwise), are likely to have been conceived in significant part either while employed by the Company or as a direct result of knowledge Executive had of
Confidential Information. Accordingly, Executive undertakes and agrees to inform the Company of any such ideas, inventions or discoveries without delay and the same shall be presumed to have been conceived during his employment with the Company,
unless and until the contrary is clearly established by Executive. Executive may be required to provide written confirmation of the existence or absence (as applicable) of any such ideas, inventions or discoveries at any time up to six
(6) months following the end of the Employment Period. 
 5.5 Inventions. Any and all writings, computer software,
inventions, improvements, processes, procedures and/or techniques which Executive may make, conceive, discover, or develop, either solely or jointly with any other Person, at any time during the Employment Period, whether at the request or upon the
suggestion of the Company or otherwise, which relate to or are useful in connection with any business now or hereafter carried on or contemplated by the Company or its Affiliate, including developments or expansions of its present fields of
operations, shall be the sole and exclusive property of the Company or its Affiliate. Executive shall take all actions necessary so that the Company or its Affiliate can prepare and present applications for copyright or Letters Patent therefor and
can secure such copyright or Letters Patent wherever possible, as well as reissue renewals, and extensions thereof, and can obtain the record title to such copyright or patents. Executive shall not be entitled to any additional or special
compensation or reimbursement regarding any such writings, computer software, inventions, improvements, processes, procedures and techniques. Executive acknowledges that the Company or its Affiliate from time to time may have agreements with other
Persons which impose obligations or restrictions on the Company or its Affiliate regarding inventions made during the course of work thereunder or regarding the confidential nature of such work. Executive agrees to be bound by all such obligations
and restrictions and to take all reasonable action which is necessary to discharge the obligations of the Company or its Affiliate with respect thereto. 

  
 14 

 Executive hereby irrevocably waives all moral rights under the Copyright, Designs and
Patents Act 1988 (and all similar rights in other jurisdictions) which he has or will have in any existing or future works referred to in Sections 5.4 and 5.5. Executive irrevocably appoints the Company to be his attorney in his name
and on his behalf to execute documents, use his name and do all things which are necessary or desirable for the Company to obtain for itself or its nominee the full benefit of these Sections 5.4 and 5.5. 

5.6 Post Termination Restrictions. 

(a) In order to protect the Confidential Information and the business, client and trade connections and the stability of the
workforce, to which the Executive has had access as a result of his employment, Executive covenants with the Company (on its own behalf and as trustee and agent for its Affiliates) that Executive shall not: 

(i) for 12 months after the Termination Date, howsoever caused, solicit or endeavour to entice away from the Company or any of
its Affiliates the business or custom of a Restricted Customer with a view to providing goods or services to that Restricted Customer in competition with any Restricted Business; 

(ii) for 12 months after the Termination Date, howsoever caused, in the course of any business concern which is or intends to
be in competition with any Restricted Business, offer to employ or engage or otherwise endeavour to entice away from the Company or any of its Affiliates any Restricted Person; 

(iii) for 12 months after the Termination Date howsoever caused, in the course of any business concern which is or intends to
be in competition with any Restricted Business, employ or engage or otherwise facilitate the employment or engagement of any Restricted Person, whether or not such person would be in breach of contract as a result of such employment or engagement;

 (iv) for 12 months after the Termination Date, howsoever caused, be involved in any Capacity with any business concern
which is (or intends to be) in competition with the Restricted Business. 
 (v) for 12 months after the Termination Date,
howsoever caused, be involved with the provision of goods or services to (or otherwise have any business dealings with) any Restricted Customer in the course of any business concern which is in competition with any Restricted Business; or

 (vi) at any time after the Termination Date, represent himself as connected with the Company or any of its Affiliates in
any Capacity, other than as a former employee, or use any registered business names or trading names associated with the Company or any of its Affiliates. 

  
 15 

 (b) None of the above restrictions in
Section 5.6(a)(i) through (vi) shall prevent Executive from: 
 (i) holding an investment by
way of shares or other securities of not more than five percent (5%) of the total issued share capital of any company, whether or not it is listed or dealt in on a recognised stock exchange; or 

(ii) being engaged or concerned in any business concern insofar as his duties or work shall relate solely to geographical areas
outside of the Restricted Area; or 
 (iii) any business with which the Executive has been involved pursuant to
Section 1.5. 
 (c) The restrictions imposed on Executive by this
Section 5.6 apply to his acting: 
 (i) directly or indirectly; and 

(ii) on his own behalf or on behalf of, or in conjunction with, any firm, company or person. 

(d) The periods for which the restrictions above apply shall be reduced by any period that Executive spends on Garden
Leave immediately before the Termination Date. 
 (e) If, during his employment under this Agreement or before the expiry of
the last of the covenants in this section, Executive receives an approach or offer to be involved in any Capacity in a business which competes with any part or parts of the Company’s business or its Affiliate’s business with which he
is or has been involved to a material extent during the Appointment, Executive shall: 
 (i) notify the Board of Directors in
writing of the fact of the approach or offer and the identity of the person making the approach or offer as soon as possible; and 

(ii) give the person making the offer a copy of this Section 5.6 within seven (7) days of the
offer being made. 
 (f) The obligations contained in this Section are continuing obligations and shall also apply if,
at any time subsequent to the relevant approach or offer being made, but before the expiry of the last of the covenants in this Section, the business making the offer or approach so competes with the Company’s or its Affiliate’s
business. 
 (g) If, at any time during Executive’s employment, one or more Restricted Persons have left their
employment, appointment or engagement with the Company or its Affiliate to carry out services for a business concern which competes with, or is intended to compete with any Restricted Business, Executive will not at any time during the six
months following the last date on which any of those Restricted Persons were employed or engaged by the Company or its Affiliate, be employed or engaged in any way with that business concern. 

  
 16 

 (h) The Parties entered into the restrictions in this Section having
been separately legally advised. 
 (i) Each of the restrictions in this Section is intended to be separate and
severable. If any of the restrictions shall be held to be void but would be valid if part of their wording were deleted, such restriction shall apply with such deletion as may be necessary to make it valid or effective. 

(j) If the Executive’s employment is transferred to any firm, company, person or entity (other than an Affiliate) (the
“New Employer”) pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, Executive will, if required, enter into an agreement with the New Employer containing post-termination restrictions
corresponding to those restrictions in this clause protecting the confidential information, clients and customer relationships, trade secrets and business connections of the New Employer. 

(k) Executive will, at the Company’s request and expense, enter into a separate agreement with any Affiliate in
which he agrees to be bound by restrictions corresponding to those restrictions in this Section (or such of those restrictions as may be appropriate) in relation to that Affiliate. 

5.7 Forfeiture of Severance Payment. A “Forfeiture Event” for purposes of this Agreement will occur if
(a) Executive knowingly or inadvertently violates any of the covenants or restrictions contained in Sections 5.1 through 5.6, or (b) the Company learns of facts within one (1) year following
Executive’s Termination Date that, if such facts had been known by the Company as of the Termination Date, would have resulted in the termination of Executive’s employment hereunder by the Company for Cause, or (c) the Executive fails
or refuses to provide upon request the written confirmation sought by the Company in Section 5.4. In the event of a Forfeiture Event, and if within thirty (30) days of being notified by the Company in writing of the
Forfeiture Event, Executive has not remedied, cured, corrected or mitigated the Forfeiture Event to the satisfaction of the Company (acting reasonably), then within a further 30 days thereafter of being notified by the Company of that fact, he shall
repay to the Company the full amount of the Additional Payment received by Executive pursuant to Section 4.1(b), net of any tax withholdings that were previously withheld from such payment. Executive specifically recognizes
and affirms that this Section 5.7 is a material part of this Agreement without which the Company would not have entered into this Agreement. Executive further covenants and agrees that should all or any part or application
of this Section 5.7 be held or found invalid or unenforceable for any reason whatsoever by a court of competent jurisdiction in an action between Executive and the Company, then Executive shall promptly pay to the Company
the amount of the Additional Payment, or such lesser amount as shall be determined to be the maximum reasonable and enforceable amount by a court, as applicable. 

  
 17 

 5.8 Removal of Restrictions by Court. It is expressly understood and
agreed that the Company and the Executive consider the restrictions contained in this Article 5 to be reasonable and necessary to protect the Confidential Information, client and customer connections, trade, workforce stability and reasonable
business interests of the Company or its Affiliates. Nevertheless, if any of the aforesaid restrictions are found by a court having jurisdiction to be unreasonable, or overly broad as to geographic area or time, or otherwise unenforceable, the
Parties intend for the unenforceable restrictions therein set forth to be deleted by such court such that the Agreement shall be reasonable and enforceable and, as such, shall then be fully enforced in the geographic area and for the time period to
the full extent permitted by law. 
 5.9 No Previous Restrictive Agreements. Executive
represents that, except for agreements he disclosed in writing to the Company, he is not bound by the terms of any agreement with any previous employer or other Person to (a) refrain from using or disclosing any trade secret or confidential or
proprietary information in the course of Executive’s employment by the Company or (b) refrain from competing, directly or indirectly, with the business of such previous employer or any other Person. Executive further represents that his
performance of all the terms of this Agreement and his work duties for the Company does not, and will not, breach any agreement to keep in confidence proprietary information, knowledge or data acquired by Executive in confidence or in trust prior to
Executive’s employment with the Company, and Executive will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or other Person. 

5.10 Conflicts of Interest. In keeping with his fiduciary duties to Company, Executive hereby agrees that he shall
not become involved in a conflict of interest, or upon discovery thereof, allow such a conflict to continue at any time during the Employment Period. Moreover, Executive agrees that he shall abide by the Company’s Code of Conduct, as it may be
amended from time to time, and immediately disclose to the Board of Directors any known facts which might involve a conflict of interest or potential conflict of interest arising of which the Board of Directors was not aware. 

5.11 Remedies. Executive acknowledges that the restrictions contained in this Article 5, in view of the nature of
the Company’s business, are reasonable and necessary to protect the Company’s legitimate business interests, and that any violation of this Agreement would result in irreparable injury to the Company. In the event of a breach or a
threatened breach by Executive of any provision of Article 5, the Company shall be entitled to claim injunctive relief restraining Executive from the commission of any breach, and to recover the Company’s attorneys’ fees, costs and
expenses related to the breach or threatened breach. Nothing contained in this Agreement shall be construed as prohibiting the Company from pursuing any other remedies available to it for any such breach or threatened breach, including, without
limitation, the recovery of money damages, attorneys’ fees, and costs. These covenants and disclosures shall each be construed as independent of any other provisions in this Agreement, and the existence of any claim or cause of action by
Executive against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by the Company of such covenants and agreements. 

The Executive acknowledges that money damages would not be sufficient remedy for any breach of Article 5 by the Executive, and the
Company shall also be entitled to specific performance as an available remedy for any such breach or any threatened breach. The remedies provided in this Section 5.11 shall not be deemed the exclusive remedies for a breach
of Article 5, but shall be in addition to all remedies available at law or in equity. 

  
 18 

 5.12 No Disparaging Comments. Executive and the Company (and its
Affiliates) shall each refrain from any criticisms or disparaging comments about each other or in any way relating to Executive’s employment or separation from employment; provided, however, that nothing in this Agreement shall apply to or
restrict in any way the communication of information by the Company or any of its Affiliates or by the Executive to any law enforcement agency, or any regulatory or compliance authority. The Company and Executive will not be in breach of this
covenant solely by reason of testimony or disclosure that is required for compliance with applicable law or regulation or by compulsion of law. A violation or threatened violation of this prohibition may be enjoined by a court of competent
jurisdiction. The rights under this provision are in addition to any and all rights and remedies otherwise afforded by law to the Parties. 

Executive acknowledges that in executing this Agreement, he has knowingly, voluntarily, and intelligently waived any free speech, free
association, free press or First Amendment to the United States Constitution (including, without limitation, any counterpart or similar provision or right under the Texas Constitution or any other state constitution which may be deemed to apply)
rights to disclose, communicate, or publish disparaging information or comments concerning or related to the Company or its Affiliate; provided, however, nothing in this Agreement shall be deemed to prevent Executive from testifying fully and
truthfully in response to a subpoena from any court or from responding to an investigative inquiry from any governmental agency. 

5.13 Company Documents and Property. All writings, records, and other documents and things comprising, containing,
describing, discussing, explaining, or evidencing any Confidential Information, and all equipment, components, parts, tools, and the like in Executive’s custody, possession or control that have been obtained or prepared in the course of
Executive’s employment with the Company shall be the exclusive property of the Company, shall not be copied and/or removed from the premises of the Company, except in pursuit of the business of the Company, and shall be delivered to the
Company, without Executive retaining any copies, extracts or parts or any electronic versions, immediately upon notification of the termination of Executive’s employment or at any other time requested by the Company. The Company shall have the
right to retain, access, and inspect all property of any kind in the office or premises of the Company. 
 5.14 Data
Protection . The Company will collect and process information relating to Executive in accordance with the privacy notice which is attached to this agreement. Executive is required to sign and date the privacy notice and return
to the General Counsel. Executive shall comply with the Company’s data protection policy when handling personal data in the course of employment` including personal data relating to any employee, worker, contractor, customer, client, supplier
or agent of the Company or its Affiliates. Executive will also comply with the Company’s “Code of Business Conduct and Ethics” and “Computer, Network & Equipment Use Policy”. Failure to comply with the
Company’s data protection policy or any of the policies listed above shall subject the Executive to discipline pursuant to the Company’s disciplinary procedures and, in serious cases, may be treated as gross misconduct leading to summary
dismissal. 
 5.15 Collective Agreements . There is no collective agreement which directly affects the
Executive’s employment. 

  
 19 

 Article 6. 

GENERAL PROVISIONS 

6.1 Matters Relating to Section 409A of the Code. Notwithstanding any provision in this
Agreement to the contrary, if the payment of any compensation or benefit provided hereunder (including, without limitation, any Termination Benefits) would be subject to additional taxes and interest under Section 409A of the Code
(“Section 409A”), then the Company may, after consulting with Executive, reform such provision to comply with Section 409A or to preclude imposition of taxes or interest under Section 409A, to the full
extent permitted under Section 409A: 
 6.2 Withholdings; Right of Deduction. The Company may withhold and deduct
from any benefits and payments made or to be made pursuant to this Agreement at any time (a) all applicable taxes and national insurance contributions as may be required pursuant to any law or governmental regulation or ruling, (b) all
other normal employee deductions made with respect to Company’s employees generally, and (c) any advances made to Executive and owed to Company. 

6.3 Nonalienation. The right to receive payments under this Agreement shall not be subject in any manner to anticipation,
alienation, sale, transfer, assignment, pledge or encumbrance by Executive, his dependents or beneficiaries, or to any other Person who is or may become entitled to receive such payments hereunder. The right to receive payments hereunder shall not
be subject to or liable for the debts, contracts, liabilities, engagements or torts of any Person who is or may become entitled to receive such payments, nor may the same be subject to attachment or seizure by any creditor of such Person under any
circumstances, and any such attempted attachment or seizure shall be void and of no force and effect. 
 6.4 Incompetent or
Minor Payees. Should the Compensation Committee determine, in its discretion, that any Person to whom any payment is payable under this Agreement has been determined to be legally incompetent or is a minor, any payment due hereunder,
notwithstanding any other provision of this Agreement to the contrary, may be made in any one or more of the following ways: (a) directly to such Person; (b) to the legal guardian or other duly appointed personal representative of the
individual or the estate of such Person; or (c) to such adult or adults as have, in the good faith knowledge of the Compensation Committee, assumed custody and support of such Person; and any payment so made shall constitute full and complete
discharge of any liability under this Agreement in respect to the amount paid. 
 6.5 Indemnification. The Company
hereby agrees to indemnify Executive and hold Executive harmless to the fullest extent permitted under the organizational documents of the Company and applicable law against and in respect of any and all actions, suits, proceedings,
claims, demands, judgments, costs, expenses (including reasonable attorney’s fees), losses, and damages (including advancement of fees and expenses) resulting from Executive’s good faith performance of Executive’s duties and
obligations with the Company hereunder. The Company shall accordingly cover Executive under directors’ and officers’ liability insurance both during and, while potential liability exists, after the Employment Period, in the same amount and
to the same extent as the Company covers its other officers and directors. The foregoing obligations shall survive the termination of Executive’s employment with the Company and shall be in addition to any other indemnification rights Executive
is entitled to, under existing or future indemnification agreements or otherwise. 

  
 20 

 6.6 Successors and Assigns. This Agreement shall be binding upon and
inure to the benefit of the Company and any successor of the Company (whether direct or indirect, by purchase, merger, consolidation or otherwise), and this Agreement shall inure to the benefit of and be enforceable by Executive’s legal
representatives. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform
this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as previously defined and any
successor by operation of law or otherwise, as well as any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement. The Company has the right and authority, in its discretion, to assign this Agreement
to a directly or indirectly fully-owned subsidiary of the Company that is domiciled in the United Kingdom and Executive hereby agrees to any such assignment or transfer. Except as provided in the preceding provisions of this
Section 6.6, this Agreement, and the rights and obligations of the Parties hereunder, are personal in nature and neither this Agreement, nor any right, benefit, or obligation of either Party hereto, shall be subject to
voluntary or involuntary assignment, alienation or transfer, whether by operation of law or otherwise, without the written consent of the other Party. 

6.7 Notice. Each Notice or other communication required or permitted under this Agreement shall be in writing and
transmitted, delivered, or sent by personal delivery, prepaid courier or messenger service (whether overnight or same-day), or prepaid certified and recorded mail (with return receipt requested), addressed (in
any case) to the other Party at the address for that Party set forth below or under that Party’s signature on this Agreement, or at such other address as the recipient has designated by Notice to the other Party. 

 

			
	To the Company:	  	VAALCO Energy, Inc.
		  	9800 Richmond Avenue, Suite 700
		  	Houston, Texas 77042
		  	Attention: General Counsel & Corporate Secretary
		
	To Executive:	  	George Maxwell
		
		  	(as set forth below his signature)

 Each Notice or communication so transmitted, delivered, or sent (a) in person, by courier or
messenger service, or by certified and recorded mail (return receipt requested) shall be deemed given, received, and effective on the date delivered to or refused by the intended recipient (with the return receipt, or the equivalent record of the
courier or messenger, being deemed conclusive evidence of delivery or refusal), or (b) by email or facsimile shall be deemed given, received, and effective on the date of actual receipt (with the confirmation of transmission being deemed
conclusive evidence of receipt, except where the intended recipient has promptly Notified the other Party that the transmission is illegible). Nevertheless, if the date of delivery or transmission is not a Business Day, or if the delivery or
transmission is after 4:00 p.m. (local time at the recipient) on a Business Day, the Notice or other communication shall be deemed given, received, and effective on the next Business Day. 

  
 21 

 6.8 Severability. It is the desire of the Parties hereto that this
Agreement be enforced to the maximum extent permitted by law, and should any provision contained herein be held unenforceable by a court of competent jurisdiction, the Parties hereby agree and consent that such provision shall be modified or deleted
to create a valid and enforceable provision to the maximum extent permitted by law; provided, however, if such provision cannot be reformed, it shall be deemed ineffective and deleted herefrom without affecting any other provision of this Agreement.
This Agreement should be construed by limiting and reducing it only to the minimum extent necessary to be enforceable under then applicable law. 

6.9 No Third Party Beneficiaries. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, and
to their respective successors and permitted assigns hereunder, but otherwise this Agreement shall not be for the benefit of any Persons who are third parties. 

6.10 Waiver of Breach. No waiver by either Party of a breach of any provision of this Agreement by the other Party, or of
compliance with any condition or provision of this Agreement to be performed by the other Party, will operate or be construed as a waiver of any subsequent breach by the other Party or any similar or dissimilar provision or condition at the same or
any subsequent time. The failure of either Party to take any action by reason of any breach will not deprive such Party of the right to take action at any time while such breach continues. 

6.11 Survival of Certain Provisions. Wherever appropriate to the intention of the Parties, the respective rights and
obligations of the Parties hereunder shall, as applicable, survive any termination or expiration of this Agreement or following the Executive’s Termination Date. 

6.12 Entire Agreement; Amendment and Termination. This Agreement contains the entire agreement of the Parties with respect
to the matters covered herein; moreover, this Agreement supersedes all prior and contemporaneous agreements and understandings, oral or written, between the Parties concerning the subject matter hereof. This Agreement may be amended, waived or
terminated only by a written instrument that is identified as an agreed amendment, waiver or termination hereto and that is executed by or on behalf of both Parties. 

6.13 Interpretive Matters. In the interpretation of the Agreement, except where the context otherwise requires: 

(a) Headings. The Agreement headings are for reference purposes only and will not affect in any way the meaning or
interpretation of this Agreement. 
 (b) The terms “including” and “include” do not denote
or imply any limitation. 
 (c) The conjunction “or” has the inclusive meaning “and/or”.

 (d) The singular includes the plural, and vice versa, and each gender includes each of the others. 

(e) The term “month” refers to a calendar month. 

  
 22 

 (f) Reference to any statute, rule, or regulation includes any amendment
thereto or any statute, rule, or regulation enacted or promulgated in replacement thereof. 
 (g) The words
“herein”, “hereof”, “hereunder” and other compounds of the word “here” shall refer to the entire Agreement and not to any particular provision; 

(h) All amounts referenced herein are in U.S. dollars. 

6.14 Governing Law; Jurisdiction. 

(a) All matters or issues relating to the interpretation, construction, validity, and enforcement of this Agreement shall be
governed by the laws of the state of Texas, without giving effect to any choice-of-law principle that would cause the application of the laws of any jurisdiction other
than Texas. 
 (b) Jurisdiction and venue of any action or proceeding relating to this Agreement or any Dispute shall be
exclusively in the federal and state courts of competent jurisdiction in Houston or Harris County, Texas. By entering into this Agreement, Executive consents to be subject to personal jurisdiction in the federal courts and Texas state courts
situated in Houston, Texas or Harris County, Texas. 
 6.15 Executive Acknowledgment. Executive acknowledges that
(a) he is knowledgeable and sophisticated as to business matters, including the subject matter of this Agreement, (b) he has read this Agreement and understands its terms and conditions, (c) he has had ample opportunity to discuss
this Agreement with his legal counsel prior to execution, and (d) no strict rules of construction shall apply for or against the drafter or any other Party. Executive represents that he is free to enter into this Agreement including, without
limitation, that he is not subject to any covenant not to compete or other restrictive covenant that would conflict with his employment duties and covenants under this Agreement. 

6.16 Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and
delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. Each counterpart may consist of a copy hereof containing multiple signature pages, each signed by one Party hereto, but together signed
by both Parties. 
 [Signature page follows.] 

  
 23 

 IN WITNESS WHEREOF, Executive has hereunto set his hand and Company has caused this
Agreement to be executed in its name and on its behalf by its duly authorized officer, to be effective as of the Effective Date. 
  

									
	WITNESS:	 		  	EXECUTIVE:
					
	Signature:	 	 /s/ R. Buchan
	 	        	  	Signature:	  	 /s/ George Maxwell

					
	Name:	 	R. Buchan	 		  	Name:	  	George Maxwell
					
	Date:	 	9 April 2021	 		  	Date:	  	9 April 2021

 Executive’s Address for Notices: 

George Maxwell  
 10 Springdale Crescent, 

Bieldside, Aberdeen AB15 9FG 
  

									
	ATTEST:	 		  	COMPANY:
			
		 	        	  	VAALCO ENERGY, INC.
					
	By:	 	 /s/ Michael G. Silver
	 		  	By:	  	 /s/ Andrew Fawthrop

					
	Name:	 	Michael G. Silver 	 		  	Name:	  	Andrew Fawthrop
					
	Title:	 	General Counsel	 		  	Title:	  	Chairman of the Board
					
	Date:	 	10 April 2021	 		  	Date:	  	9 April 2021

  
 24 

 APPENDIX A 

Definitions Appendix 

1. “Affiliate” has the same meaning ascribed to such term in Rule 12b-2
under the Securities Exchange Act of 1934, as amended from time to time. 
 2. “Anticipatory Termination” means a
Separation From Service of the Executive on or after August 1, 2021, and within the time period that begins on the first day of the month that is three (3) months immediately preceding the first day of the month containing the Change in
Control Date and ends on the Change in Control Date but only if the Executive’s Separation From Service was (a) due to a termination by the Company without Cause or (b) a termination by the Executive for Good Reason. For purposes of
clarification and not limitation, a Separation From Service for Cause, or due to Executive’s death or Disability or his voluntary resignation without Good Reason, is not an Anticipatory Termination. 

3. “Arbitration Rules” means the Rules for Employment Arbitrations of the American Arbitration Association, as in
effect at the time of arbitration of a Dispute. 
 4. “Board” means the then-current Board of Directors of the
Company. 
 5. “Business Day” means any Monday through Friday, excluding any such day on which banks are authorized
to be closed in Texas. 
 6. “Capacity” means as agent, consultant, director, employee, worker, owner, partner or
shareholder. 
 7. “Cause” shall mean the termination by the Company of the Executive’s employment with the
Company in circumstances of: 
 (a) any act or omission of Executive which constitutes gross misconduct and which has been
determined by the Board of Directors, acting reasonably, to be so; 
 (b) the conviction of the Executive of a criminal
offence by a court of competent jurisdiction of a crime involving moral turpitude or which is a crime other than an offence under any road traffic legislation in the UK or elsewhere) for which a fine or
non-custodial penalty is imposed; 
 (c) Executive being disqualified from acting as
a director or resigning as a director from the Company without the prior written approval of the Board of Directors; 
 (d)
the commission by the Executive of a material act of fraud or dishonesty upon the Company or any of its Affiliates, or any customer or supplier thereof; 

(e) the misappropriation of any funds or property of the Company or any of its Affiliates, or any customer or supplier thereof,
by the Executive; 

  
 A-1 

 (f) the Executive’s gross negligence or gross incompetence or otherwise
the willful and continued failure by the Executive to perform the material duties assigned to him that is not cured to the reasonable satisfaction of the Company within 30 days after written notice of such failure is provided to Executive by the
Board or the Compensation Committee (or by an officer of the Company who has been designated by the Board or the Compensation Committee for such purpose); 

(g) the engagement by the Executive in any direct and material conflict of interest with the Company or any of its Affiliates
without compliance with the Company’s conflict of interest policy (or the conflict of interest policy of any Affiliate of the Company, if any) then in effect; 

(h) the violation by the Executive of the Company’s “Code of Business Conduct and Ethics” or the
Executive’s serious breach of the Company’s rules and policies (including but not limited to the “Employee Handbook”, “Anti-Bribery and Anti-Tax Avoidance Compliance Policy”,
“Insider Trading Policy”, “Computer, Network & Equipment Use Policy”, and other policies and procedures related to Company rules on electronic communications); 

(i) the engagement by the Executive, without the written approval of the Board or the Compensation Committee, in any material
activity which competes with the business of the Company or any of its Affiliates or which would result in a material injury to the business, reputation or goodwill of the Company or any of its Affiliates; 

(j) the Executive is declared bankrupt or makes any arrangement with or for the benefit of his creditors or have a county court
administration order made against you under the County Court Act 1984; or 
 (k) the Executive is, in the opinion of a
medical practitioner physically or mentally incapable of performing his duties and may remain so for more than three months and the medical practitioner has given a medical opinion to the Board of Directors to that effect; or 

(l) ceases to be eligible to work in the UK. 

8. “Change in Control” means the occurrence of any one or more of the following events: 

(a) The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange
Act (a “Person”)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either (i) the then outstanding shares of
common stock of the Company (the “Outstanding Company Stock”) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the
“Outstanding Company Voting Securities”); provided, however, that the following acquisitions shall not constitute a Change in Control: (i) any acquisition directly from the Company or any Subsidiary, (ii) any acquisition
by the Company or any Subsidiary or by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary, or (iii) any acquisition by any corporation pursuant to a reorganization, merger, consolidation or
similar business combination involving the Company (a “Merger”), if, following such Merger, the conditions described in Section 7.8(c) (below) are satisfied; 

  
 A-2 

 (b) Individuals who, as of the Effective Date, constitute the Board of
Directors of the Company (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or
nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered a member of the Incumbent Board, but excluding, for this purpose, any
such individual whose initial assumption of office occurs as a result of either an actual or threatened election contest (as such terms are used in Rule 14a-11 of Regulation 14A promulgated under the Exchange
Act) or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; 

(c) The consummation of a Merger involving the Company, unless immediately following such Merger, (i) substantially all of
the holders of the Outstanding Company Voting Securities immediately prior to Merger beneficially own, directly or indirectly, more than fifty percent (50%) of the common stock of the corporation resulting from such Merger (or its parent
corporation) in substantially the same proportions as their ownership of Outstanding Company Voting Securities immediately prior to such Merger and (ii) at least a majority of the members of the board of directors of the corporation resulting
from such Merger (or its parent corporation) were members of the Incumbent Board at the time of the execution of the initial agreement providing for such Merger; or 

(d) The sale consummation, or other disposition of all or substantially all of the assets of the Company, unless immediately
following such sale or other disposition, (i) substantially all of the holders of the Outstanding Company Voting Securities immediately prior to the consummation of such sale or other disposition beneficially own, directly or indirectly, more
than fifty percent (50%) of the common stock of the corporation acquiring such assets in substantially the same proportions as their ownership of Outstanding Company Voting Securities immediately prior to the consummation of such sale or
disposition, and (ii) at least a majority of the members of the board of directors of such corporation (or its parent corporation) were members of the Incumbent Board at the time of execution of the initial agreement or action of the Board of
Directors providing for such sale or other disposition of assets of the Company; or 
 (e) The approval by the stockholders
of the Company or the Board of a plan for the complete liquidation or dissolution of the Company. 
 Notwithstanding the foregoing
provisions of this Change in Control definition, to the extent that any payment (or acceleration of payment) under the Agreement is considered to be deferred compensation that is subject to, and not exempt under, Code Section 409A, then the
term Change in Control hereunder shall be construed to have the meaning as set forth in Code Section 409A, but only with respect to the payment (or acceleration of payment) of such deferred compensation, and to the extent inconsistent with the
foregoing provisions of this definition as determined by the Incumbent Board. 

  
 A-3 

 9. “Change in Control Date” means the first date upon which a Change
in Control event occurs, provided that such date occurs (a) during either (i) the Employment Period or (ii) the three-month period following the end of the Employment Period as specified in the definition of “Anticipatory
Termination” if applicable, and (b) is, in any event, on or after August 1, 2021. 
 10. “CIC Window
Period” means (a) the time period beginning on the Change in Control Date and ending on the last day of the twelve (12) consecutive month period that begins immediately following the last day of the month containing the Change in
Control Date, or (b) following an Anticipatory Termination, the occurrence of a Change in Control (which Change in Control must qualify as a “change in control event” within the meaning of Section 409A) within the three-month
period that is specified in the definition of “Anticipatory Termination”. 
 11. “Code” means the Internal
Revenue Code of 1986, as amended, or its successor. References herein to any Section of the Code shall include any successor provisions of the Code. 

12. “Confidential Information” means any information or material known to, or used by or for, the Company or an
Affiliate (whether or not owned or developed by the Company or an Affiliate and whether or not developed by Executive) that is not generally known by other Persons in the Business. For all purposes of the Agreement, Confidential Information
includes, but is not limited to, the following: all trade secrets of the Company or an Affiliate; all non-public information that the Company or an Affiliate has marked as confidential or has otherwise
described to Executive (either in writing or orally) as confidential; all non-public information concerning the Company’s or Affiliate’s products, services, prospective products or services,
research, prospects, leases, surveys, seismic data, drilling data, designs, prices, costs, marketing plans, marketing techniques, studies, test data, leasehold and royalty owners, investors, suppliers and contracts; all business records and plans;
all personnel files; all financial information of or concerning the Company or an Affiliate; all information relating to the Company’s operating system software, application software, software and system methodology, hardware platforms,
technical information, inventions, computer programs and listings, source codes, object codes, copyrights and other intellectual property; all technical specifications; any proprietary information belonging to the Company or an Affiliate; all
computer hardware or software manuals of the Company or an Affiliate; all Company or Affiliate training or instruction manuals; all Company or Affiliate electronic data; and all computer system passwords and user codes. 

13. “Designated Beneficiary” means Executive’s surviving spouse, if any, as determined for purposes of the Code.
If there is no such surviving spouse at the time of Executive’s death, then the Designated Beneficiary shall be Executive’s estate. 

14. “Disability” shall mean that Executive is entitled to receive long-term
disability (“LTD”) income benefits under the LTD plan or policy maintained by the Company or an Affiliate that covers Executive. If, for any reason, Executive is not covered under such LTD plan or policy, then “Disability”
shall mean a “permanent and total disability” as defined in Code Section 22(e)(3) and Treasury regulations thereunder. Evidence of such Disability shall be certified by a physician acceptable to both the Company and Executive. In the
event that the Parties are not able to agree 

  
 A-4 

 
on the choice of a physician, each shall select one physician who, in turn, shall select a third physician to render such certification. All costs relating to the determination of whether
Executive has incurred a Disability shall be paid by the Company. Executive agrees to submit to any examinations that are reasonably required by the attending physician or other healthcare service providers to determine whether he has a Disability.

 15. “Dispute” means any dispute, disagreement, controversy, claim, or cause of action arising in connection with
or relating to this Agreement or Executive’s employment or termination of employment hereunder, or the validity, interpretation, performance, breach, modification or termination of this Agreement. 

16. “Good Reason” means, with respect to Executive, the occurrence of any one or more of the following
events which first occurs during the Employment Period, except as a result of actions taken in connection with termination of Executive’s employment for Cause or Disability, and without Executive’s specific written consent: 

(a) The assignment to Executive of any duties that are materially inconsistent with Executive’s executive position, which in this
definition includes status, reporting relationship to the Board of Directors, office, title, scope of responsibility over corporate level staff or operations functions, or responsibilities as an officer of the Company, or any other material
diminution in Executive’s position, authority, duties, or responsibilities, other than (in any case or circumstance) an isolated and inadvertent action not taken in bad faith that is remedied by the Company within thirty (30) Business Days
after Notice thereof to the Company by Executive; or 
 (b) The Company requires Executive to be based at any office or location that is
farther than forty (40) miles from Executive’s principal office location located in the London, UK metropolitan area, except for required business travel; or 

(c) Any failure by the Company to obtain an assumption of this Agreement by its successor in interest, or any action or inaction that
constitutes a material breach by the Company of this Agreement. 
 Notwithstanding the foregoing definition of “Good Reason”,
Executive cannot terminate his employment under the Agreement for Good Reason unless Executive (1) first provides written Notice to the Compensation Committee of the event (or events) that Executive believes constitutes a Good Reason event
(above) within sixty (60) days from the first occurrence date of such event, and (2) provides the Company with at least thirty (30) Business Days to cure, correct or mitigate the Good Reason event so that it either (A) does not
constitute a Good Reason event hereunder or (B) Executive specifically agrees, in writing, that after any such modification or accommodation by the Company, such event does not constitute a Good Reason event hereunder. 

17. “Garden Leave” means any period under which the Company has exercised its rights under
Section 4.6. 
 18. “Incapacity” means any sickness, injury or other medical disorder or
condition which prevents Executive from carrying out his duties. 

  
 A-5 

 19. “No Severance Benefits Event” means termination of
Executive’s employment under the Agreement for Cause. 
 20. “Notice” means a written communication complying
with Section 6.7 (“Notify” has the correlative meaning). 
 21. “Notice of
Termination” means a written Notice which (a) indicates the specific termination provision in the Agreement that is being relied upon, (b) to the extent applicable, sets forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of Executive’s employment under the provision so indicated, and (c) if the Termination Date is other than the date of receipt of such Notice, specifies the termination date (which date shall be
not more than sixty (60) days after the giving of such Notice). Any termination of Executive by the Company for Cause, or by Executive for Good Reason, shall be communicated by Notice of Termination to the other Party. The failure by Executive
or the Company to set forth in the Notice of Termination any fact or circumstance that contributes to a showing of Good Reason or Cause shall not waive any right of such Party, or preclude such Party from asserting, such fact or circumstance in
enforcing such Party’s rights. 
 22. “Person” means any individual, firm, corporation, partnership, limited
liability company, trust, or other entity, including any successor (by merger or otherwise) of such entity. 
 23. “Restricted
Area” means any geographical area (a) in which the Company or any of its Affiliates has operations or otherwise undertakes its or their business or (b) in relation to which, as at the Termination Date, the Company or any of its
Affiliates has taken any action that discloses an intent to have operations or undertake its or their business therein. For avoidance of doubt, the Restricted Area as of the Effective Date comprises Gabon and Equatorial Guinea including their
respective territorial waters. 
 24. “Restricted Business” means those parts of the Company’s or its
Affiliate’s business with which Executive was involved or concerned to a material extent in the 12 months before the Termination Date. 

25. “Restricted Customer” means any firm, company, person or other entity who, during the twelve (12) months
before the Termination Date, was a customer or prospective customer of or was in the habit of dealing with the Company or its Affiliate and with whom Executive had contact or about whom he became aware or informed or was introduced to by the Company
or its Affiliate in the course of his employment. This definition shall not include any firm, person, company or other entity with whom the Executive had a prior relationship, or with whom he had worked, or done business with before the date of the
commencement of this Agreement except with respect to any operations or other business of the Company or any of its Affiliates relating to the Restricted Area. 

26. “Restricted Person” means anyone employed or engaged by the Company or its Affiliate at the level of manager,
officer or above or who could materially damage the interest of the Company or its Affiliate if they were involved in any Capacity in any business concern which competes (or intends to compete) with any Restricted Business and with whom the
Executive dealt in the twelve (12) months before the Termination Date in the course of his employment. 

  
 A-6 

 27. “Settlement Agreement” means a settlement agreement, in such
form as is prepared and delivered by the Company to Executive. The Settlement Agreement shall not release any claim by or on behalf of Executive for any payment or other benefit which is required under this Agreement and not conditioned upon
execution and non-revocation of the Settlement Agreement by Executive prior to the receipt thereof, except as may otherwise be agreed to by Executive. 

28. “Severance Payment Event” means either a (a) “CIC Severance Payment Event” or (b) “Regular Severance
Payment Event”, as such terms are defined below. 
 (a) “CIC Severance Payment Event” means either: the
Executive’s Separation From Service with the Company and all Affiliates that occurs within the CIC Window Period, other than (1) voluntarily by the Executive unless such resignation is for Good Reason, (2) due to Executive’s
death or Disability, or (3) involuntarily by the Company for Cause. Notwithstanding any provision herein to the contrary, any Separation From Service of the Executive that (i) does not occur within the CIC Window Period or (ii) is
otherwise not described in this subsection (a), shall not be considered a CIC Severance Payment Event. 
 (b)
“Regular Severance Payment Event” means a Separation From Service that is not a CIC Severance Payment Event and such Separation From Service is due to: (1) involuntarily termination of Executive’s Employment by the
Company, except due to a No Severance Benefits Event, (2) termination of Executive’s Employment due to his death or Disability, or (3) termination of Executive’s Employment for Good Reason. 

For all purposes of this definition of “Severance Payment Event”, any transfer of the Executive’s Employment from the Company to an Affiliate,
from an Affiliate to the Company, or from one Affiliate to another Affiliate, is not a Separation From Service of the Executive (though any such transfer might, depending on the circumstances, constitute or result in a Separation From Service by the
Executive for Good Reason). Any termination by the Company of the Executive for Cause, or by the Executive for Good Reason, shall be communicated by Notice of Termination to the other Party. 

29. “Specialized Training” includes the training the Company provides to Executive that is unique to its business and
enhances Executive’s ability to perform his job duties effectively, which includes, without limitation, orientation training, operation methods training, and computer and systems training. 

30. “Subsidiary” means a corporation or other entity, whether incorporated or unincorporated, of which at least a
majority of the voting securities is owned, directly or indirectly, by the Company. 
 31. “Termination Benefits”
means the benefits described in Section 4.1(b). 
 32. “Termination Date” means the date on
which Executive’s employment terminates with the Company and all Affiliates. 

  
 A-7 

 APPENDIX B 

Form Settlement Agreement 

DATED 
  

 

SETTLEMENT AGREEMENT 

between 
 VAALCO ENERGY, INC.

 and 
 GEORGE MAXWELL

  
 B-1 

 CONTENTS 

CLAUSE 
  

							
	 1.
	  	 Interpretation
	  	 	4	 
			
	 2.
	  	 Arrangements on termination
	  	 	5	 
			
	 3.
	  	 Termination Benefits
	  	 	6	 
			
	 4.
	  	 Legal fees
	  	 	7	 
			
	 5.
	  	 Waiver of claims
	  	 	7	 
			
	 6.
	  	 Executive indemnities
	  	 	9	 
			
	 7.
	  	 Company property and information
	  	 	10	 
			
	 8.
	  	 Executive warranties and acknowledgments
	  	 	10	 
			
	 9.
	  	 Resignation from offices
	  	 	11	 
			
	 10.
	  	 [Garden leave
	  	 	11	 
			
	 11.
	  	 Restrictive Covenants
	  	 	11	 
			
	 12.
	  	 Confidentiality and announcements
	  	 	11	 
			
	 13.
	  	 Directors & Officers Insurance and Company Indemnity
	  	 	13	 
			
	 14.
	  	 Entire agreement
	  	 	14	 
			
	 15.
	  	 Variation
	  	 	14	 
			
	 16.
	  	 Third party rights
	  	 	14	 
			
	 17.
	  	 Governing law
	  	 	14	 
			
	 18.
	  	 Jurisdiction
	  	 	14	 
			
	 19.
	  	 Subject to contract and without prejudice
	  	 	15	 
			
	 20.
	  	 Counterparts
	  	 	15	 

  
 B-2 

 SCHEDULE 
  

					
	 Schedule 1
	  	Calculation of the Termination Benefits	  	16
			
	 Schedule 2
	  	Claims	  	17
			
	 Schedule 3
	  	Advisers certificate	  	21
			
	 Schedule 4
	  	Announcement	  	22
			
	 Schedule 5
	  	Restrictive covenants	  	23

  
 B-3 

 This agreement is dated [DATE]. 

Parties 
  

	(1)	 VAALCO ENERGY, INC., incorporated in the United States, State of Delaware (“Company / we /
us”) 

  

	(2)	 George Maxwell of [INDIVIDUAL ADDRESS] (“Executive / you”) 

BACKGROUND 
  

	(A)	 You [have been OR were] employed by us from [DATE], most recently as [POSITION] under an employment
agreement (“Employment Agreement”) dated [DATE]. 

  

	(B)	 Your employment with us [shall terminate OR terminated] on [DATE]. 

 

	(C)	 The parties have entered into this agreement to record and implement the terms on which they have agreed to
settle any claims that are set out herein and which you have or may have in connection with your employment or its termination or otherwise against us or any Group Company (as defined below) or our or their officers, employees or workers, whether or
not those claims are, or could be, in the contemplation of the parties at the time of signing this agreement, and including, in particular, the statutory complaints that you raise in this agreement. 

 

	(D)	 The parties intend this agreement to be an effective waiver of any such claims and to satisfy the conditions
relating to settlement agreements and compromise contracts in the relevant legislation. 

  

	(E)	 We enter into this agreement for ourselves and as agent and trustee for all Group Companies and we are
authorised to do so. It is the parties intention that each Group Company should be able to enforce any rights it has under this agreement, subject to and in accordance with the Contracts (Rights of Third Parties) Act 1999. 

Agreed terms 
  

	1.	 Interpretation 

The following definitions and rules of interpretation apply in this agreement. 

 

	1.1	 Definitions: 

Adviser: [NAME] of [FIRM]. 

Affiliate: has the same meaning ascribed to such term in Rule 12b-2 under the Securities
Exchange Act of 1934, as amended from time to time 

  
 B-4 

 Board: the then-current board of directors of the Company (including any committee of
the board duly appointed by it). 
 Confidential Information: has the meaning given in Section 12 of Appendix A to the Employment
Agreement. 
 Group Company: the Company, its Affiliates, subsidiaries or holding companies from time to time and any subsidiary of
any holding company from time to time. 
 Holding company: has the meaning given in clause 1.6. 

Post-Employment Notice Pay: has the meaning given in section 402D of the Income Tax (Earnings and Pensions) Act 2003 (ITEPA). 

Post-Employment Notice Period: has the meaning given in section 402E(5) of ITEPA. 

Subsidiary: has the meaning in clause 1.6. 

Termination Benefits: as defined in the Employment Agreement under Article 4. 

 

	1.2	 The headings in this agreement are inserted for convenience only and shall not affect its construction.

  

	1.3	 A reference to a particular law is a reference to it as it is in force for the time being taking account of any
amendment, extension, or re-enactment and includes any subordinate legislation for the time being in force made under it. 

 

	1.4	 Unless the context otherwise requires, words in the singular shall include the plural and in the plural shall
include the singular. 

  

	1.5	 The Schedules shall form part of this agreement and shall have effect as if set out in full in the body of this
agreement. Any reference to this agreement includes the Schedules. 

  

	1.6	 A reference to a holding company or a subsidiary means a holding company or a subsidiary (as the case may be)
as defined in section 1159 of the Companies Act 2006 [and a company shall be treated, for the purposes only of the membership requirement contained in sections 1159(1)(b) and (c), as a member of another company even if its shares in that other
company are registered in the name of (a) another person (or its nominee), whether by way of security or in connection with the taking of security, or (b) as a nominee]. 

 

	2.	 Arrangements on termination 

 

	2.1	 Your employment with the Company [shall terminate OR terminated] on [DATE] (“Termination
Date”). 

  
 B-5 

	2.2	 The parties acknowledge that pursuant to clause 4.3 of your Employment Agreement in order to receive the
Termination Benefits (as defined in that Agreement) you are required to enter into this Settlement Agreement and confirm the waiver of the Claims (as defined below and contained herein accordingly). The parties agree that any other payments
contractually due to you under your Employment Agreement, (whether pre or post termination), or those subsisting post termination contractual rights given to you by the Employment Agreement which are not expressly waived as set out herein, are
unaffected by this Agreement. Your compliance with entry into and the terms of this Agreement means the Termination Benefits shall be paid to you hereunder, as stated and as previously as set out in the Employment Agreement. 

 

	2.3	 At the Termination Date, you confirm that you [have OR will have] completed the period of notice to which you
are entitled under Section 2.2 of the Employment Agreement and we confirm that we will [have paid OR will pay] your salary [and benefits] for that period. [The parties accordingly believe that your Post-Employment Notice Period and
Post-Employment Notice Pay are nil. 

  

	3.	 Termination Benefits 

 

	3.1	 Subject to and conditional on you complying with the terms of this agreement, including, without limitation,
clause 12, we shall [within 30 days of the Termination Date or receipt by us of a copy of this agreement signed by you in the form as set out in Schedule 3, whichever is later], pay to you as consideration for your performance under this agreement
and by way of compensation for the termination of your employment the Termination Benefits (“Termination Benefits”) calculated in accordance with the terms of Article 4 of the Employment Agreement, as applicable and set out in Schedule 1.
We will pay the Termination Benefits less all required deductions for tax and National Insurance contributions. In this regard, the parties believe the following to be correct: 

 

	 	(a)	 [No part of the Termination Benefits is taxable as Post-Employment Notice Pay.] OR [The [first
£[AMOUNT] (or USD equivalent calculated in accordance with clause 3.4 below) of the] Termination Benefits is Post-Employment Notice Pay and is taxable as earnings. We shall accordingly deduct income tax and employee National Insurance
contributions from it at the appropriate rate.] 

  

	 	(b)	 [The [[next £30,000 OR first £30,000 OR balance] (or USD equivalent calculated in
accordance with clause 3.4 below) of the Termination Benefits will be tax free, as a termination award under the threshold within the meaning of sections 402A(1) and 403 of ITEPA.] 

 

	 	(c)	 [The balance of the Termination Benefits will be taxable as a termination award exceeding the threshold within
the meaning of sections 402A(1) and 403 of ITEPA. We shall accordingly deduct income tax from it at the appropriate rate.] 

  
 B-6 

	3.2	 You shall be responsible for any further tax and employees National Insurance contributions due in respect of
the Termination Benefits, and you shall indemnify us in respect of such liability in accordance with clause 6.1. 

  

	3.3	 [The Termination Benefits will be paid to you [before OR after] receipt by you of your P45.]

  

	3.4	 Where the Termination Benefits or any sums hereunder are indicated in GBP Sterling but are to be paid to you in
US Dollars (although subject to UK taxation as General Earnings under ITEPA Sections 15 or 27) the amounts chargeable hereunder to tax shall be strictly the GBP Sterling equivalent at the date you are entitled to be paid those sums or the date they
are paid (if earlier). The conversion between these currencies should be calculated using the daily spot exchange rate of the Bank of England in operation at the relevant date. 

 

	4.	 Legal fees 

We shall pay the reasonable legal fees (up to a maximum of £[AMOUNT] plus VAT) incurred by you in obtaining advice on the termination of
your employment and the terms of this agreement, such fees to be payable to the Adviser on production of an invoice addressed to you but marked as payable by us. 
  

	5.	 Waiver of claims 

 

	5.1	 You agree that the terms of this agreement are offered by us without any admission of liability on our part and
are in full and final settlement of all and any claims or rights of action that you have or may have against us or any Group Company or our or its officers, employees or workers arising out of your employment with us or its termination, whether
under common law, contract, statute or otherwise, whether such claims are, or could be, known to the parties or in their contemplation at the date of this agreement in any jurisdiction and including, but not limited to, the specific claims set out
in Part A of Schedule 2 and also the claims specified in Part B of Schedule 2 (together “the Claims” and each of which claims in Part A and Part B is hereby waived by this clause). 

 

	5.2	 The waiver in clause 5.1 shall not apply to the following: 

 

	 	(a)	 any claims by you to enforce this agreement; and 

 

	 	(b)	 claims in respect of personal injury of which you are not aware and could not reasonably be expected to be
aware at the date of this agreement (other than claims under discrimination legislation); 

  

	 	(c)	 your existing entitlement to contractual payments or contractual rights given to you which subsist
post-termination and in each case, which are set out in your Employment Agreement, pursuant to clause 2.2 above (and so are outside the ambit of this agreement); 

  
 B-7 

	 	(d)	 [if applicable, your claim to any Remaining Additional Payment Amount (as defined in the Employment Agreement
under Section 4.1) if such entitlement arises after your entry into this Settlement Agreement]. 

  

	5.3	 You warrant that: 

  

	 	(a)	 before entering into this agreement you received independent advice from the Adviser as to the terms and effect
of this agreement and, in particular, on its effect on your ability to pursue the Claims specified in this agreement; 

  

	 	(b)	 the Adviser has confirmed to you that they are a solicitor holding a current practising certificate and that
there is in force a policy of insurance covering the risk of a claim by you in respect of any loss arising in consequence of their advice; 

  

	 	(c)	 the Adviser shall sign and deliver to us a letter in the form attached as Schedule 3 to this agreement;

  

	 	(d)	 before receiving the advice you disclosed to the Adviser all facts and circumstances in respect of the Claims
and/or that may give rise to a claim by you against us or any Group Company or our or its officers, employees or workers; 

  

	 	(e)	 You have not filed (and will not file) any complaints, claims or actions against the Company or any Group
Company or its or their officers, employees or workers with any court, agency or commission regarding matters encompassed by this agreement; 

  

	 	(f)	 the only claims that you have or may have against the Company or any Group Company or our or its officers,
employees or workers (whether at the time of entering into this agreement or in the future) relating to your employment with us or its termination are the Claims, and as specified in clause 5.1 and Schedule 2; and. 

 

	 	(g)	 You are not aware of any facts or circumstances that may give rise to any claim against us or any Group Company
or our or its officers, employees or workers other than the Claims and/or those claims specified in clause 5.1 and Schedule 2 which are hereby waived. 

You acknowledge that we acted in reliance on these warranties when entering into this agreement. The Company acknowledges that the above
warranties (f) and (g) shall not apply insofar as they relate to matters specifically excluded from Section 5.1 of this Settlement Agreement, pursuant to clause 5.2. 

  
 B-8 

	5.4	 You acknowledge that the conditions relating to settlement agreements and compromise contracts under section
147(3) of the Equality Act 2010, section 77(4A) of the Sex Discrimination Act 1975 (in relation to claims under that Act and the Equal Pay Act 1970), section 72(4A) of the Race Relations Act 1976, paragraph 2 of Schedule 3A to the Disability
Discrimination Act 1995, paragraph 2(2) of Schedule 4 to the Employment Equality (Sexual Orientation) Regulations 2003, paragraph 2(2) of Schedule 4 to the Employment Equality (Religion or Belief) Regulations 2003, paragraph 2(2) of Schedule 5 to
the Employment Equality (Age) Regulations 2006, section 288(2B) of the Trade Union and Labour Relations (Consolidation) Act 1992, section 203(3) of the Employment Rights Act 1996, regulation 35(3) of the Working Time Regulations 1998, section 49(4)
of the National Minimum Wage Act 1998, regulation 41(4) of the Transnational Information and Consultation etc. Regulations 1999, regulation 9 of the Part-Time Workers (Prevention of Less Favourable Treatment) Regulations 2000, regulation 10 of the
Fixed-Term Employees (Prevention of Less Favourable Treatment) Regulations 2002, regulation 40(4) of the Information and Consultation of Employees Regulations 2004, paragraph 13 of the Schedule to the Occupational and Personal Pension Schemes
(Consultation by Employers and Miscellaneous Amendment) Regulations 2006, regulation 62 of the Companies (Cross Border Mergers) Regulations 2007 and section 58 of the Pensions Act 2008 have been satisfied. 

 

	5.5	 The waiver in clause 5.1 shall have effect irrespective of whether or not, at the date of this agreement, you
are or could be aware of such claims or have such claims in your express contemplation (including such claims of which you become aware after the date of this agreement in whole or in part as a result of new legislation or the development of common
law or equity). 

  

	5.6	 You agree that, except for the Termination Benefits provided for in this agreement, and subject to the
provisions in clause 5.2, and any continuing contractual entitlements under the Employment Agreement pursuant to clause 2.2, above you shall not be eligible for any further or different payment or compensation from us or any Group Company relating
to your employment or its termination and you expressly waive any right or claim that you have or may have to such payment or arrangement or award you may have received had your employment not terminated. 

 

	6.	 Executive indemnities 

 

	6.1	 You shall indemnify us on a continuing basis in respect of any income tax or National Insurance contributions
(save for employers National Insurance contributions) due in respect of (a) the payments and benefits in clause 3.1 and (b) any Remaining Additional Payment Amount (if any) which may become payable to you (and any related interest,
penalties, costs and expenses). We shall give you reasonable notice of any demand for tax which may lead to liabilities on you under this indemnity and shall provide you with reasonable access to any documentation you may reasonably require to
dispute such a claim (provided that nothing in this clause shall prevent us from complying with our legal obligations with regard to HM Revenue and Customs or other competent body). 

  
 B-9 

	6.2	 If you breach any provision of this agreement or pursue a claim against us or any Group Company arising out of
your employment or its termination other than those excluded under clause 5, you agree to indemnify us or any Group Company for any losses suffered as a result thereof, including all reasonable legal and professional fees incurred.

  

	7.	 Company property and information 

 

	7.1	 Notwithstanding clause 14 and the termination of your employment, you acknowledge that: 

 

	 	(a)	 Sections 5.3, 5.4, 5.5, and 5.6 of the Employment Agreement will continue to apply after the Termination Date
and you shall continue to comply with the same; and 

  

	 	(b)	 Sections 5.7 and 5.11 of the Employment Agreement shall continue to apply to any breach or threatened breach of
Sections 5.3, 5.4, 5.5, and 5.6 of the Employment Agreement. 

  

	7.2	 You shall, before the Termination Date, erase OR as at the date of this agreement, warrant that you have
erased irretrievably any information relating to our or any Group Company’s business or affairs or our or its business contacts from computer and communications systems and devices owned or used by you outside our premises, including such
systems and data storage services provided by third parties (to the extent technically practicable). 

  

	7.3	 You shall, if requested to do so by the Board of Directors, provide a signed statement that you have complied
fully with your obligations under clause 7.1 and clause 7.2 and shall provide us with such reasonable evidence of compliance as may be requested. 

  

	8.	 Executive warranties and acknowledgments 

 

	8.1	 As at the date of this agreement, you hereby warrant and represent to us that you have not undertaken any
conduct which would be a Forfeiture Event as defined in Section 5.7 of the Employment Agreement and you are aware that any payment to you pursuant to clause 3 above is conditional on this being so. 

 

	8.2	 You agree to make yourself available to, and to cooperate with, us or our advisers in any internal
investigation or administrative, regulatory, judicial or quasi-judicial proceedings. You acknowledge that this could involve, but is not limited to, responding to or defending any regulatory or legal process, providing information in relation to any
such process, preparing witness statements and giving evidence in person on our behalf. We shall reimburse any loss of earnings or reasonable expenses that you incur as a consequence of complying with your obligations under this clause, provided
that such expenses are approved in advance by us. 

  
 B-10 

	9.	 Resignation from offices 

 

	9.1	 You [acknowledge that you have resigned from your position as [POSITION] and] shall resign immediately from any
[other] office, trusteeship or position that you hold in or on [our OR any Group Company’s] behalf. 

  

	9.2	 [You irrevocably appoint us to be your attorney in your name and on your behalf to sign, execute or do any such
instrument or thing and generally to use your name in order to give us (or our nominee) the full benefit of the provisions of this clause.] 

  

	10.	 [Garden leave 

 

	10.1	 During the period from [DATE] to the Termination Date you shall not perform any services for us or any
Affiliate (“Garden Leave”), and shall comply with the provisions of Section 4.6 of the Employment Agreement accordingly.] 

11. Restrictive covenants 
  

	11.1	 Notwithstanding clause 14, you acknowledge that the post-termination restrictions in Article 5 of the
Employment Agreement will continue to apply after the Termination Date [save that the period of each will be reduced by the period that you spend on Garden Leave] and which, for clarity are set out at Schedule 5 to this Agreement.

  

	11.2	 We shall pay £100 to you as consideration for your entering into the restrictive covenants in Schedule 5,
such sum to be paid within 30 days after the Termination Date or receipt by us of a copy of this agreement signed by you and receipt by us of a letter from the Adviser as set out in Schedule 3, whichever is later. We shall deduct income tax and
National Insurance contributions from this sum 

  

	12.	 Confidentiality and announcements 

 

	12.1	 Notwithstanding clause 14, and the termination of your employment, you acknowledge that: 

 

	 	(a)	 Sections 5.1 and 5.2 of the Employment Agreement will continue to apply after the Termination Date and you
shall continue to comply with the same; and 

  

	 	(b)	 Sections 5.7 and 5.11 of the Employment Agreement shall continue to apply to any breach or threatened breach of
those Sections 5.1 and 5.2. 

  
 B-11 

	12.2	 The parties confirm that they have kept and agree to keep the existence and terms of this agreement and the
circumstances concerning the termination of your employment confidential, save only: 

  

	 	(a)	 as provided in clause 12.4, clause 12.5 and clause 12.6; 

 

	 	(b)	 [to the extent required to complete our investigation into your grievance raised [on [DATE] OR [in your
letter dated [DATE]] and any subsequent disciplinary investigation or procedure]; or 

  

	 	(c)	 as required by law or regulatory practice. 

 

	12.3	 The parties shall continue to comply with Section 5.12 of the Employment Agreement notwithstanding the
termination of your employment. You acknowledge that Section 5.7 and 5.11 of the Employment Agreement shall continue to apply to any breach or threatened breach of Section 5.12. This clause is subject to clause 12.4, clause 12.5 and clause
12.6. 

  

	12.4	 The parties are permitted to make a disclosure or comment that would otherwise be prohibited by clause 12.3 and
clause 12.4 if, where necessary and appropriate: 

  

	 	(a)	 in your case, you make it to: 

 

	 	(i)	 your spouse, civil partner or partner or immediate family provided that they agree to keep the information
confidential; or 

  

	 	(ii)	 any person who owes you a duty of confidentiality (which you agree not to waive) in respect of information you
disclose to them, including your legal or tax advisers or persons providing you with medical, therapeutic, counselling or support services; or 

  

	 	(iii)	 your insurer for the purposes of processing a claim for loss of employment; [or] 

 

	 	(iv)	 [your recruitment consultant or prospective employer to the extent necessary to discuss your employment
history; [or]] 

  

	 	(v)	 [any government benefits agency for the purposes of you making a claim for benefits; and]

  

	 	(b)	 in our case, we make it to: 

 

	 	(vi)	 our officers, employees or workers provided that they agree to keep the information confidential; or

  

	 	(vii)	 any person who owes us a duty of confidentiality (which we agree not to waive) in respect of information we
disclose to them, including, our legal, tax, compliance or other professional advisers. 

  
 B-12 

	12.5	 Nothing in this clause 12 shall prevent you or any of our officers, employees, workers or agents from making a
protected disclosure under section 43A of the Employment Rights Act 1996. 

  

	12.6	 Nothing in this clause 12 shall prevent you or us (or any of our officers, employees, workers or agents) from:

  

	 	(a)	 reporting a suspected criminal offence to the police or any law enforcement agency or co-operating with the police or any law enforcement agency regarding a criminal investigation or prosecution; or 

  

	 	(b)	 doing or saying anything that is required by HMRC or a regulator, ombudsman or supervisory authority; or

  

	 	(c)	 whether required to or not, making a disclosure to, or co-operating
with any investigation by, HMRC or a regulator, ombudsman or supervisory authority regarding any misconduct, wrongdoing or serious breach of regulatory requirements (including giving evidence at a hearing); or 

 

	 	(d)	 complying with an order from a court or tribunal to disclose or give evidence; or 

 

	 	(e)	 disclosing information to HMRC for the purposes of establishing and paying (or recouping) tax and national
insurance liabilities arising from your employment or its termination; or 

  

	 	(f)	 making any other disclosure as required by law. 

 

	12.7	 We will make an announcement on [the Termination Date OR signature of this agreement] in the form set
out in Schedule 4 and neither party will make any statement to third parties (save as specified in clause 12.5, clause 12.6 or clause 12.7) which is inconsistent with that announcement. 

 

	12.8	 We shall pay £100 to you as consideration for your entering into the restrictions in this clause 12, such
sum to be paid within 30 days of the Termination Date or receipt by us of a copy of this agreement signed by you and receipt by us of a letter from the Adviser as set out in Schedule 3 whichever is later. We shall deduct income tax and National
Insurance contributions from this sum. 

  

	13.	 Directors & Officers Insurance and Company Indemnity 

 

	13.1	 Notwithstanding the termination of your employment, the Company shall continue to indemnify you subject to and
in accordance with Section 6.5 of the Employment Agreement, as it does for its other directors and officers of similar standing, for acts undertaken during your employment. 

  
 B-13 

	14.	 Entire agreement 

Each party on behalf of itself and, in our case, as agent for any Group Company acknowledges and agrees with the other party (with us acting on
our own behalf and as agent for each Group Company) that: 
  

	 	(a)	 This agreement and the Employment Agreement (where the latter is referenced in this agreement accordingly, and
in particular by clause 2.2 above) together constitute the entire agreement between the parties and any Group Company and this agreement and the Employment Agreement (where the latter is referenced in this agreement) together supersede and
extinguish all agreements, promises, assurances, warranties, representations and understandings between them whether written or oral, relating to the subject matter of this agreement; 

 

	 	(b)	 in entering into this agreement, it does not rely on, and shall have no remedies in respect of, any statement,
representation, assurance or warranty (whether made innocently or negligently) that is not set out in this agreement or referenced in this agreement; and 

  

	 	(c)	 it shall have no claim for innocent or negligent misrepresentation or negligent misstatement based on any
statement in this agreement. 

  

	15.	 Variation 

No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives). 

 

	16.	 Third party rights 

Except as expressly provided elsewhere in this agreement, no person other than you and [us OR any Group Company] shall have any rights
under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement. [This does not affect any right or remedy of a third party which exists, or is available, apart from that Act.] 

 

	17.	 Governing law 

This agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales. 
  

	18.	 Jurisdiction 

Each party irrevocably agrees that the courts of England and Wales shall have [exclusive OR
non-exclusive] jurisdiction to settle any dispute or claim arising out of or in connection with this agreement or its subject matter or formation (including
non-contractual disputes or claims). 

  
 B-14 

	19.	 Subject to contract and without prejudice 

This agreement shall be deemed to be without prejudice and subject to contract until such time as it is signed by both parties and dated, when
it shall be treated as an open document evidencing a binding agreement. 
  

	20.	 Counterparts 

This agreement may be executed in any number of counterparts, each of which shall constitute a duplicate original, but all the counterparts
shall together constitute the one agreement. 
 This agreement has been entered into on the date stated at the beginning of it. 

  
 B-15 

 Schedule 1 Calculation of the Termination Benefits 

  
 B-16 

 Schedule 2 Claims 

Part A – Specific Claims 
  

	1.	 Claims: 

[SET OUT SPECIFIC CLAIMS] 
 [Claims below to
be divided into those specific claims which have been intimated by the Executive to his Legal Adviser (Part A) and included here and all other UK employment-related claims which are also being waived (Part B)].  

Part B – Other Claims 
  

	2.	 Claims: 

  

	2.1	 for breach of contract or wrongful dismissal; 

 

	2.2	 for unfair dismissal, under section 111 of the Employment Rights Act 1996; 

 

	2.3	 in relation to the right to a written statement of reasons for dismissal, under section 93 of the Employment
Rights Act 1996; 

  

	2.4	 for a statutory redundancy payment, under section 163 of the Employment Rights Act 1996; 

 

	2.5	 in relation to an unlawful deduction from wages or unlawful payment, under section 23 of the Employment Rights
Act 1996; 

  

	2.6	 for unlawful detriment, under section 48 of the Employment Rights Act 1996 or section 56 of the Pensions Act
2008; 

  

	2.7	 in relation to written employment particulars and itemised pay statements, under section 11 of the Employment
Rights Act 1996; 

  

	2.8	 in relation to guarantee payments, under section 34 of the Employment Rights Act 1996; 

 

	2.9	 in relation to suspension from work, under section 70 of the Employment Rights Act 1996; 

 

	2.10	 in relation to parental leave, under section 80 of the Employment Rights Act 1996; 

 

	2.11	 in relation to a request for flexible working, under section 80H of the Employment Rights Act 1996;

  
 B-17 

	2.12	 in relation to time off work, under sections 51, 54, 57, 57B, 57ZC, 57ZF, 57ZH, 57ZM, 57ZQ, 60, 63 and 63C of
the Employment Rights Act 1996; 

  

	2.13	 in relation to working time or holiday pay, under regulation 30 of the Working Time Regulations 1998;

  

	2.14	 in relation to the national minimum wage, under sections 11, 18, 19D and 24 of the National Minimum Wage Act
1998; 

  

	2.15	 for equal pay or equality of terms under sections 120 and 127 of the Equality Act 2010 and/or section 2 of the
Equal Pay Act 1970; 

  

	2.16	 for pregnancy or maternity discrimination, direct or indirect discrimination, harassment or victimisation
related to sex, marital or civil partnership status, pregnancy or maternity or gender reassignment under section 120 of the Equality Act 2010 and/or direct or indirect discrimination, harassment or victimisation related to sex, marital or civil
partnership status, gender reassignment, pregnancy or maternity under section 63 of the Sex Discrimination Act 1975; 

  

	2.17	 for direct or indirect discrimination, harassment or victimisation related to race under section 120 of the
Equality Act 2010 and/or direct or indirect discrimination, harassment or victimisation related to race, colour, nationality or ethnic or national origin, under section 54 of the Race Relations Act 1976 

 

	2.18	 for direct or indirect discrimination, harassment or victimisation related to disability, discrimination
arising from disability, or failure to make adjustments under section 120 of the Equality Act 2010 and/or direct discrimination, harassment or victimisation related to disability, disability-related discrimination or failure to make adjustments
under section 17A of the Disability Discrimination Act 1995; 

  

	2.19	 for direct or indirect discrimination, harassment or victimisation related to religion or belief under section
120 of the Equality Act 2010 and/or under regulation 28 of the Employment Equality (Religion or Belief) Regulations 2003; 

  

	2.20	 for direct or indirect discrimination, harassment or victimisation related to sexual orientation, under section
120 of the Equality Act 2010 and/or under regulation 28 of the Employment Equality (Sexual Orientation) Regulations 2003; 

  

	2.21	 for direct or indirect discrimination, harassment or victimisation related to age, under section 120 of the
Equality Act 2010 and/or under regulation 36 of the Employment Equality (Age) Regulations 2006 

  
 B-18 

	2.22	 for less favourable treatment on the grounds of part-time status, under regulation 8 of the Part-Time Workers
(Prevention of Less Favourable Treatment) Regulations 2000; 

  

	2.23	 for less favourable treatment on the grounds of fixed-term status, under regulation 7 of the Fixed-Term
Employees (Prevention of Less Favourable Treatment) Regulations 2002; 

  

	2.24	 under regulations 27 and 32 of the Transnational Information and Consultation of Employees Regulations 1999;

  

	2.25	 under regulations 29 and 33 of the Information and Consultation of Employees Regulations 2004;

  

	2.26	 under regulations 45 and 51 of the Companies (Cross-Border Mergers) Regulations 2007; 

 

	2.27	 under paragraphs 4 and 8 of the Schedule to the Occupational and Personal Pension Schemes (Consultation by
Employers and Miscellaneous Amendment) Regulations 2006; 

  

	2.28	 under sections 68A, 87, 137, 145A, 145B, 146, 168, 168A, 169, 170, 174 and 192 of the Trade Union and Labour
Relations (Consolidation) Act 1992; 

  

	2.29	 in relation to the obligations to elect appropriate representatives or any entitlement to compensation, under
the Transfer of Undertakings (Protection of Employment) Regulations 2006; 

  

	2.30	 in relation to the right to be accompanied under section 11 of the Employment Relations Act 1999;

  

	2.31	 in relation to refusal of employment, refusal of employment agency services and detriment under regulations 5,
6 and 9 of the Employment Relations Act 1999 (Blacklists) Regulations 2010; 

  

	2.32	 in relation to the right to request time off for study or training under section 63I of the Employment Rights
Act 1996; 

  

	2.33	 in relation to the right to equal treatment, access to collective facilities and amenities, access to
employment vacancies and the right not to be subjected to a detriment under regulations 5, 12, 13 and 17(2) of the Agency Workers Regulations 2010; 

  

	2.34	 in relation to the right to a written statement and the right not to be unfairly dismissed or subjected to
detriment under regulations 4 and 5 of the Agency Workers (Amendment) Regulations 2019; 

  
 B-19 

	2.35	 in relation to personal injury, of which you are or ought reasonably to be aware at the date of this agreement;

  

	2.36	 for harassment under the Protection from Harassment Act 1997; 

 

	2.37	 for failure to comply with obligations under the Human Rights Act 1998; 

 

	2.38	 for failure to comply with obligations under the Data Protection Act 1998, the Data Protection Act 2018, the
General Data Protection Regulation ((EU) 2016/679) [as it has effect in EU law], or the UK GDPR as defined in section 3(10) and section 205(4) of the Data Protection Act 2018; 

 

	1.39	 arising as a consequence of the United Kingdoms former membership of the European Union; an1.40 in relation to
the right not to be subjected to a detriment under regulation 3 of the Exclusivity Terms in Zero Hours Contracts (Redress) Regulations 2015. 

  

	1.41	 arising under any US federal, state or local laws of any jurisdiction that prohibit age, sex, race, national
origin, color, disability, religion, veteran, military status, sexual orientation or any other form of discrimination, harassment, hostile work environment or retaliation (including, without limitation, the Age Discrimination in Employment Act of
1967, the Older Workers Benefit Protection Act, the Americans with Disabilities Act of 1990, the Americans with Disabilities Act Amendments Act of 2008, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Civil Rights Acts
of 1866 and/or 1871, 42 U.S.C. Section 1981, the Rehabilitation Act, the Family and Medical Leave Act, the Sarbanes-Oxley Act, the Employee Polygraph Protection Act, the Worker Adjustment and Retraining Notification Act, the Equal Pay Act of
1963, the Lilly Ledbetter Fair Pay Act, the Uniformed Services Employment and Reemployment Rights Act of 1994, the Genetic Information and Nondiscrimination Act of 2008, the Texas Labor Code, Section 1558 of the Patient Protection and
Affordable Care Act of 2010, the Consolidated Omnibus Budget Reconciliation Act of 1985, and any other federal, state or local laws of any jurisdiction); 

  

	1.42	 under any other US federal, state, local, municipal or common law whistleblower protection, discrimination,
wrongful discharge, anti-harassment or anti-retaliation statute or ordinance; 

  

	1.43	 arising under ERISA; 

 

	1.44	 in respect of any illegal or wrongful acts by any of the Released Parties, including, without limitation,
discrimination, retaliation, harassment or any other wrongful act based on sex, age, race, religion, or any other legally protected characteristic; or 

  

	1.45	 regarding any other US statutory or common law matters related to Executives employment or separation from
employment with the Company and its Affiliates. 

  
 B-20 

 Schedule 3 Advisers certificate 

[ON HEADED NOTEPAPER OF ADVISER] 
 For the attention of [DETAILS]

 [DATE] 
 [[Dear [NAME OF FIRM]] OR [To whom it may
concern],] 
 I am writing in connection with the agreement between my client, [NAME], and [NAME OF COMPANY] (Company) [of todays date OR dated
[DATE]] (Agreement) to confirm that: 
 1. I, [NAME] of [FIRM], whose address is [ADDRESS], am [a Solicitor of the Senior Courts of England and Wales who
holds a current practising certificate OR AMEND AS APPLICABLE]. 
 2. I have given [NAME] legal advice on the terms and effect of the Agreement and,
in particular, [its OR their] effect on my clients ability to pursue the claims specified in Schedule 2 of the Agreement. 
 3. I gave the advice to
[NAME] as a relevant independent adviser within the meaning of the above acts and regulations referred to at clause 5.4. 
 4. There is now in force (and was
in force at the time I gave the advice referred to above) a policy of insurance or an indemnity provided for members of a profession or professional body covering the risk of claim by my client in respect of loss arising in consequence of the advice
I have given them. 
 Yours faithfully, 
 [NAME OF ADVISER]

 [DATE] 

  
 B-21 

 Schedule 4 Announcement 

[INSERT THE TEXT OF THE AGREED ANNOUNCEMENT] 

  
 B-22 

 Schedule 5 Restrictive covenants 

[INSERT THE RESTRICTIVE COVENANTS] 

  
 B-23 

			
	 Signed by [NAME OF DIRECTOR OR
 OTHER AUTHORISED
SIGNATORY] for
 and on behalf of [NAME OF COMPANY]
	  	                                      
                                  
		
		  	[Director OR [POSITION]]
		
	Signed by [NAME OF EXECUTIVE]	  	                                      
                                  

  
 B-24gmvp_ex101.htm

EXHIBIT 10.1
    
 EXCHANGE AGREEMENT
  
 THIS EXCHANGE AGREEMENT (the “Agreement”) is made as of the 9th day of April, 2021 by and between Gridiron Nutrients, Inc., a Nevada corporation (the “Company”), and the holder signatory hereto (the “Holder”).
  
 WHEREAS, the Holder has from time to time previously acquired from the Company certain of the Company’s securities as set forth on Schedule I (the “Securities”).
  
 WHEREAS, the Company has authorized a new series of convertible preferred stock designated as Series B Convertible Preferred Stock, $0.001 par value (the “Series B”), the terms of which are set forth in the Certificate of Designations for such series of Series B Preferred Stock (the “Certificate of Designations”) in the form attached hereto as Exhibit A.
  
 WHEREAS, subject to the satisfaction of the conditions set forth herein, the Company and the Holder desire to enter into a transaction wherein the Company shall issue such aggregate number of shares of Series B described on Schedule I in exchange for the Securities as set forth on Schedule I.
  
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
  
 1. Exchange. The closing of the Exchange (the “Closing”) will occur following the satisfaction or waiver of the conditions set forth herein (such date, the “Closing Date”). On the Closing Date, subject to the terms and conditions of this Agreement, each Holder shall, and the Company shall, pursuant to Section 3(a)(9) of the Securities Act of 1933 (the “Securities Act”), exchange the Securities for the Series B in accordance with the Certificate of Designations and in the amounts set forth on Schedule I hereto. At the Closing, the following transactions shall occur (such transactions in this Section 1, the “Exchange”):
  
 1.1. The Company shall issue the Series B to the Holder (or its designees). Promptly after the Closing Date, the Company shall deliver a certificate evidencing the Series B to the Holder. On the Closing Date, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Series B and shall have the right to convert the Series B, subject to the Certificate of Designations, irrespective of the date the Company delivers the certificate evidencing the Series B to the Holder.
  
 1.2. Upon receipt of the Series B in accordance with Section 1.1, all of the Holder’s rights under the Securities shall be extinguished and all such Securities shall be deemed cancelled and no longer outstanding.
  
 1.3. The Company and the Holder shall execute and/or deliver such other documents and agreements as are customary and reasonably necessary to effectuate the Exchange.
  
 1.4. If the Closing has not occurred on or prior to April 30, 2021, the Holder shall have the right, by delivery of written notice to the Company, to terminate this Agreement (such date, the “Termination Date”). From the date hereof until the earlier of (x) the Closing Date (as defined below) and (y) the Termination Date, the Holder shall forbear from taking any actions with respect to the Securities not explicitly set forth herein, including, without limitation, conversions, exercises, redemptions, exchanges or delivery of written notice to the Company to require the conversion, exercise, redemption or exchange of any of the Securities.
  
 1.5. At or before the Closing, the Holder shall deliver or cause to be delivered to Pearlman Law Group, LLP, as counsel to the Company, (i) the executed Agreement, (ii) certificates, promissory notes and warrants previously issued to Holder representing the Securities and appropriate stock powers, and (iii) other items required to effectuate the Exchange.
  
 2. Representations and Warranties of the Company. The Company hereby represents and warrants to the Holder that:
   
 	 
	1
	

	 

   
 2.1. Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect (as defined below) on its business or properties. As used in this Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Exchange or by the agreements and instruments to be entered into (or entered into) in connection herewith or therewith, or on the authority or ability of the Company to perform its obligations under this Agreement or the Exchange.
  
 2.2. Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement and the other documents and agreements incident to the Exchange and the performance of all obligations of the Company hereunder and thereunder, and the authorization of the Exchange and the issuance (and reservation for issuance) of the Series B and the shares of the Company’s common stock (the “Common Stock”) issuable upon conversion of the Series B have been taken on or prior to the date hereof. The Certificate of Designations has been validly filed with the Secretary of State of Nevada and, as of the date hereof and the Closing Date, remains in full force and effect.
  
 2.3. Valid Issuance of the Series B; Holding Period of Series B. The Series B shares when issued and delivered in accordance with the terms of this Agreement, for the consideration expressed herein, and the Common Stock when issued in accordance with the terms of the Certificate of Designations, for the consideration expressed therein, will be duly and validly issued, fully paid and non-assessable. As of the Closing, the Company shall have reserved from its duly authorized capital stock not less than 125% of the maximum number of shares of Common Stock issuable upon conversion of the Series B (assuming for purposes hereof that such Series B are convertible at the initial Conversion Price (as defined in the Certificate of Designations) and any such reservation shall not take into account any limitations on the conversion of the Series B set forth in the Certificate of Designations). The Company agrees to take all actions, including, without limitation, the issuance by its legal counsel of any appropriate legal opinions, necessary to issue unrestricted Common Stock pursuant to Section 3(a)(9) of the Securities Act and Rule 144 thereunder upon conversion of the Series B, such that the Common Stock will be freely tradable without restriction and not containing any restrictive legend without the need for any action by the Holder other than as required by Rule 144(b)(2) and Rule 144(i) and execution of the applicable representation letter(s).
  
 2.4. Exemption from Registration; Compliance With Laws. The offer and issuance of the Series B as contemplated by this Agreement is exempt from the registration requirements of the Securities Act. Neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption(s). The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably be expected to have a Material Adverse Effect, and the Company has not received written notice of any such violation.
  
 2.5. Consents; Waivers. No consent, waiver, approval or authority of any nature, or other formal action, by any Person, not already obtained, is required in connection with the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions provided for herein and therein. As used in this Agreement, “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
  
 2.6. Acknowledgment Regarding Holder’s Exchange of Securities for Series B Shares. The Company acknowledges and agrees that each Holder is acting solely in the capacity of an arm’s length security holder with respect to this Agreement and the Exchange and the transactions contemplated hereby and thereby and that the Holder is not an officer or director of the Company or (ii) to the knowledge of the Company, as of the date hereof a “beneficial owner” of more than 10% of the outstanding shares of Common Stock (as defined for purposes of Rule 13d-3 under the Securities Exchange Act of 1934). The Company further acknowledges that each Holder is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Exchange and the transactions contemplated hereby and thereby, and any advice given by the Holder or any of its representatives or agents in connection with the Exchange and the transactions contemplated hereby and thereby is merely incidental to the Holder’s acceptance of the Series B. The Company further represents to the Holder that the Company’s decision to enter into the Exchange has been based solely on the independent evaluation by the Company and its representatives.
   
 	 
	2
	

	 

  
 2.7. Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company, the Common Stock, the Securities or any of the Company’s officers or directors in their capacities as such which would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
  
 2.8. Validity; Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Company or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company is a party or by which it is bound, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities or “blue sky” laws) applicable to the Company, except in the case of clause (ii) above, for such conflicts, defaults or rights which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.
  
 2.9. Disclosure. The Company confirms that neither it nor any other person acting on its behalf has provided the Holder or its agents or counsel with any information that constitutes or could reasonably be expected to constitute material, nonpublic information. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company.
  
 2.10. No Commission Paid. Neither the Company nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the foregoing, has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section 3(a)(9) of the Securities Act and the rules and regulations of the Securities and Exchange Commission (the “Commission”) promulgated thereunder) for soliciting the Exchange.
  
 2.11 Professional Fees.The Company hereby represents and warrants that it is “current” in professional fees payable to the professionals who have been engaged to provide services to the Company, including, but not limited to, its auditors, accountants, attorneys, EDGAR filing agent and transfer agent (collectively, the “Professionals”).
  
 3. Representations and Warranties of the Holder. The Holder hereby represents, warrants and covenants that:
  
 3.1. Authorization. The Holder has full power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery of this Agreement, the performance of its obligations hereunder and the consummation of the transactions contemplated hereby.
  
 3.2. Accredited Investor Status; Investment Experience. The Holder is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D. The Holder can bear the economic risk of its ownership of the Series B, and has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the Exchange and the terms of the Series B.
  
 3.3. No Governmental Review. The Holder understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Series B or the fairness or suitability of an investment in the Series B nor have such authorities passed upon or endorsed the merits of the offering of the Series B.
   
 	 
	3
	

	 

  
 3.4. Validity; Enforcement; No Conflicts. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Holder and shall constitute the legal, valid and binding obligations of the Holder enforceable against the Holder in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.
  
 3.5. Ownership of Securities. The Holder owns and holds, beneficially and of record, the entire right, title, and interest in and to the Securities free and clear of all liens and encumbrances. The Holder has full power and authority to transfer and dispose of the Securities to the Company free and clear of any right or lien. Other than the transactions contemplated by this Agreement, there is no outstanding, plan, pending proposal, or other right of any Person to acquire all or any part of the Securities or any shares of Common Stock issuable upon conversion of the Securities.
  
 3.6 Information on the Company.The Holder has been provided access to the Company’s annual, quarterly and current reports filed with the Commission pursuant to Section 12(g) of the Securities Exchange Act of 1934 via the Commission’s public website at www.sec.gov/EDGAR (the “SEC Reports”), and represents and warrants that the Holder has read and reviewed the SEC Reports.The Holder has relied solely on the SEC Reports in making its decision to acquire the Securities. The Holder is not relying on any documents or other information other than the SEC Reports in connection with its decision to enter into this Agreement and the Exchange.
  
 4. Conditions to Closing.
  
 4.1. Conditions to Holder’s Obligations. The obligation of the Holder to consummate the Exchange is subject to the fulfillment, to the Holder’s reasonable satisfaction, prior to or at the Closing, of each of the following conditions:
  
 4.1.1. Representations and Warranties. The representations and warranties of the Company contained in this Agreement shall be true and correct in all material respects on the date hereof and on and as of the Closing Date as if made on and as of such date.
  
 4.1.2. Issuance of Securities; Filing of Certificate of Designations. At the Closing, the Company shall issue a certificate evidencing the Series B, registered in the name of the Holder and evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of Nevada.
  
 4.1.3. No Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit or obtain substantial damages in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.
  
 4.1.4. Proceedings and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident to such transactions shall be satisfactory in substance and form to the Holder, and the Holder shall have received all such counterpart originals or certified or other copies of such documents as they may reasonably request.
  
 4.1.5. Consents. The Company shall have obtained all required consents and approvals required to effect the transaction hereunder.
  
 4.2. Conditions to the Company’s Obligations. The obligation of the Company to consummate the Exchange is subject to the fulfillment, to the Company’s reasonable satisfaction, prior to or at the Closing, of each of the following conditions:
  
 4.2.1. Representations and Warranties. The representations and warranties of the Holder contained in this Agreement shall be true and correct in all material respects on the date hereof and on and as of the Closing Date as if made on and as of such date.
   
 	 
	4
	

	 

  
 4.2.2. No Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit, or obtain substantial damages in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.
  
 4.2.3. Proceedings and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident to such transactions shall be satisfactory in substance and form to the Company and the Company shall have received all such counterpart originals or certified or other copies of such documents as the Company may reasonably request. The Holder shall deliver the original Securities to the Company.
  
 5. Additional Covenants.
  
 5.1. Disclosure. The Company shall, on or before 8:30 a.m., New York time, on the first business day after the Closing, file with the Commission a Current Report on Form 8-K disclosing all material terms of the transactions contemplated hereby and attaching the form of this Agreement and the Certificate of Designations as exhibits thereto (collectively with all exhibits attached thereto, the “8-K Filing”). From and after the issuance of the 8-K Filing, the Holder shall not be in possession of any material, nonpublic information received from the Company or any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that is not disclosed in the 8-K Filing. The Company shall not, and shall cause its officers, directors, employees, affiliates and agents, not to, provide the Holder with any material, nonpublic information regarding the Company from and after the filing of the 8-K Filing without the express written consent of the Holder. To the extent that the Company delivers any material, non-public information to the Holder without the Holder’s express prior written consent, the Company hereby covenants and agrees that the Holder shall not have any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agent with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, employees, affiliates or agent or not to trade on the basis of, such material, non-public information. The Company shall not disclose the name of the Holder in any filing, announcement, release or otherwise, unless such disclosure is required by law or regulation. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company.
  
 5.2. Holding Period. For the purposes of Rule 144 of the Securities Act, the Company acknowledges that (i) the holding period of the Securities may be tacked onto the holding period of the Series B as long as no payment is made in connection with any conversion of the Series B for shares of Common Stock, and (ii) the holding period of the Series B may be tacked onto the holding period of the Common Stock, and the Company agrees not to take a position contrary to this Section 5.2, subject to any future amendment or Commission interpretation to applicable federal securities law.
  
 5.3. Blue Sky. The Company shall make all filings and reports relating to the Exchange required under applicable securities or “Blue Sky” laws of the states of the United States following the date hereof, if any.
  
 5.4. Fees and Expenses. Other than $7,000 of legal fees of Cavalry that the Company shall pay at Closing, each party to this Agreement shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.
  
 6. Miscellaneous.
  
 6.1. Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
   
 	 
	5
	

	 

  
 6.2. Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.
  
 6.3. Notices. All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently given if delivered to the addressees in person, by FedEx or similar overnight next business day delivery, or by email followed by overnight next business day delivery, to the address as provided for on the signature page to this agreement.
  
 6.4. Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Holder.
  
 6.5. Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).
  
 6.6. Counterparts. This Agreement may be executed in two or more counterparts, via PDF or electronic signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
  
 6.7. Survival. The representations, warranties and covenants of the Company and the Holder contained herein shall survive the Closing and delivery of the Series B.
  
 [SIGNATURES ON THE FOLLOWING PAGE]
   
 	 
	6
	

	 

    
 IN WITNESS WHEREOF, this Agreement is executed as of the date first set forth above.
  
 	 GRIDIRON NUTRIENTS, INC.
	
	 	 	 
	By:	/s/ Timothy S. Orr	
	 Name: 
	Timothy S. Orr	 
	Its:	 President and CEO
	 

  
 	 Address for Notice:
	  
	 6991 East Camelback Road
 Suite D-300
 Scottsdale, AZ85251
 email: tim@gridironmvp.com

      
 	 HOLDER Calvary Fund I LP
	
	 	 	 
	By:	/s/ Thomas Walsh	
	 Name: 
	Thomas Walsh	 
	Its:	Manager	 

 
 Address for Notice:
   
 	 
	7
	

	 

   
 
 Schedule I
  
 	 Description of Securities
	  
	  
	  

	  
	  
	  
	  

	 $30,000 principal amount 10% Original Issue Discount 10% Convertible Redeemable Secured Note Due February 27, 2020, as extended
	  
	  
	  

	  
	  
	  
	  

	 $140,000 principal amount 10% Original Issue Discount 10% Convertible Redeemable Secured Note Due May 25, 2020, as extended 
	  
	  
	  

	  
	  
	  
	  

	 $555,000 principal amount 10% Original Issue Discount 10% Convertible Redeemable Senior Secured Note Due July 27, 2020, as extended 
	  
	  
	  

	  
	  
	  
	  

	 $259,615.35 principal amount 10% Original Issue Discount Self-Amortizing Convertible Note Due February 15, 2021
	  
	  
	  

	  
	  
	  
	  

	 8,480,000 shares of Series A Convertible Preferred Stock
	  
	  
	  

	  
	  
	  
	  

	 Warrant to purchase Common Stock dated July 30, 2018 
	  
	  
	  

	  
	  
	  
	  

	 Total No. of shares of Series B to be Issued in Exchange for the Securities
	  
	 2,694,514
	  

   
 	 
	8
	

	 

  
 EXHIBIT A
  
 CERTIFICATE OF DESIGNATIONS, PREFERENCES
 AND RIGHTS OF THE
SERIES B CONVERTIBLE PREFERRED STOCK OF 
 GRIDIRON BIONUTRIENTS, INC.
   
 The undersigned, Timothy S. Orr, Chief Executive Officer of Gridiron BioNutrients, Inc. (the “Corporation”), a corporation organized and existing under the Nevada Revised Statutes (the “NRS”), hereby does certify:
  
 That pursuant to the authority expressly conferred upon the Board of Directors of the Corporation by the Corporation’s Articles of Incorporation, as amended, and Section 78.315 of the NRS, the Board of Directors on March 17, 2021, adopted the following resolution determining it desirable and in the best interests of the Corporation and its shareholders for the Corporation to create a series of Two Million Six Hundred Ninety Four Thousand Five Hundred Fourteen (2,694,514) shares of preferred stock designated as “Series B Convertible Preferred Stock”, none of which shares have been issued.
  
 RESOLVED, that the Board of Directors designates the Series B Convertible Preferred Stock and the number of shares constituting such series, and fixes the rights, powers, preferences, privileges and restrictions relating to such series in addition to any set forth in the Articles of Incorporation as follows:
  
 TERMS OF SERIES B CONVERTIBLE PREFERRED STOCK
  
 1. Certain Defined Terms. For purposes of this Certificate of Designations, the following terms shall have the following meanings:
  
 (a) “1934 Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.
  
 (b) “Additional Amount” means, as of the applicable date of determination, with respect to each share of Series B, all dividends, whether declared or not, on such share of Series B.
  
 (c) “Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that “control” of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.
  
 (d) “Applicable Price” shall have the meaning given to it in Section 8 hereto.
  
 (e) “Approved Stock Plan” means any employee benefit plan or agreement which has been approved by the Board of Directors of the Corporation prior to or subsequent to the Initial Issuance Date pursuant to which shares of Common Stock and standard options to purchase Common Stock may be issued to any employee, officer, consultant or director for services provided to the Corporation in their capacity as such.
   
 	 
	9
	

	 

  
 (f) “Authorized Failure Shares” shall have the meaning given to it in Section 11 hereto.
  
 (g) “Authorized Share Allocation” shall have the meaning given to it in Section 11 hereto.
  
 (h) “Authorized Share Failure” shall have the meaning given to it in Section 11 hereto.
  
 (i) “Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in the City of New York are authorized or required by law to remain closed.
  
 (j) “Buy-In Price” shall have the meaning given to it in Section 5 hereto.
  
 (k) “Cavalry” shall have the meaning given to it in Section 3 hereto.
  
 (l) “Certificate of Designations” means this Certificate of Designations, Preferences and Rights of the Series B Convertible Preferred Stock of the Corporation.
  
 (m) “Closing Date” shall have the meaning set forth in the Exchange Agreement, which date the Corporation initially issued the Series B pursuant to the terms of the Exchange Agreement.
  
 (n) “Closing Sale Price” means, for any security as of any date, (i) last closing trade price for such security on the Principal Market, as reported by Bloomberg, or, (2) if the foregoing does not apply, the lowest reported sale price for such date on the Principal Market, or (3) fair market value as determined by the Board of Directors of the Corporation.
  
 (o) “Common Stock” means (i) the Corporation’s shares of common stock, $0.001 par value per share, and (ii) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.
  
 (p) “Consideration Value” means the value of the applicable Option, Convertible Security as of the date of issuance thereof (as determined by the Board of Directors in good faith).
  
 (q) “Conversion Amount” shall have the meaning given to it in Section 5 hereto.
  
 (r) “Conversion Date” shall have the meaning given to it in Section 5 hereto.
  
 	 
	10
	

	 

  
 (s) “Conversion Failure” shall have the meaning given to it in Section 5 hereto.
  
 (t) “Conversion Notice” shall have the meaning given to it in Section 5 hereto.
  
 (u) “Conversion Price” shall have the meaning given to it in Section 5 hereto.
  
 (v) “Conversion Rate” shall have the meaning given to it in Section 5 hereto.
  
 (w) “Convertible Securities” means any stock or other security (other than Options) that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock
  
 (x) “Corporate Event” shall have the meaning given to it in Section 7 hereto.
  
 (y) “Corporation” shall have the meaning given to it in the preamble hereto.
  
 (z) “Dilutive Issuance” shall have the meaning given to it in Section 8 hereto.
  
 (aa) “Dispute Submission Deadline” shall have the meaning given to it in Section 22 hereto.
  
 (bb) “Distributions” shall have the meaning given to it in Section 14 hereto.
  
 (cc) “DTC” shall have the meaning given to it in Section 5 hereto.
  
 (dd) “Excess Shares” shall have the meaning given to it in Section 5 hereto.
  
 (ee) “Exchange Agreement” means that certain exchange agreement by and among the Corporation and the initial holders of Series B, dated as of the Subscription Date, as may be amended from time in accordance with the terms thereof.
  
 (ff) “Excluded Securities” means (i) shares of Common Stock, restricted stock units or standard options to purchase Common Stock issued to directors, officers or employees of the Corporation for services rendered to the Corporation in their capacity as such pursuant to an Approved Stock Plan, provided that the exercise price of any such options is not lowered, none of such options are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that adversely affects any of the Investors; (ii) the shares of Common Stock issuable upon conversion of the Series B or otherwise pursuant to the terms of the Certificate of Designations; provided, that the terms of the Certificate of Designations are not amended, modified or changed on or after the Closing Date (other than anti-dilution adjustments pursuant to the terms thereof in effect as of the Closing Date), (iii) securities issued to consultants, suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors of the Company as long as such securities are issued as "restricted securities" (as defined in Rule 144) or; (iv) securities issued pursuant to a merger, acquisition or similar transaction; provided that (A) the primary purpose of such issuance is not to raise capital, (B) the purchaser or acquirer of such securities in such issuance solely consists of either (1) the actual participants in such transactions, (2) the actual owners of such assets or securities acquired in such merger, acquisition or similar transaction, (3) the shareholders, partners or members of the foregoing Persons and (4) Persons whose primary business does not consist of investing in securities, and (C) the number or amount (as the case may be) of such shares of Common Stock issued to such Person by the Corporation shall not be disproportionate to such Person’s actual ownership of such assets or securities to be acquired by the Corporation (as applicable).
  
 	 
	11
	

	 

  
 (gg) “Fundamental Transaction” shall have the meaning given to it in Section 7.
  
 (hh) “Group” means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.
  
 (ii) “Holder” or “Holders” means a holder of Series B.
  
 (jj) “Initial Issuance Date” means, with respect to each Holder, the date such Holder initially acquired shares of Series B.
  
 (kk) “Junior Stock” shall have the meaning given to it in Section 3 hereto.
  
 (ll) “Late Charge” shall have the meaning any amount due under the Transaction Documents which is not paid when due which shall result in a late charge being incurred and payable by the Corporation in an amount equal to interest on such amount at the rate of eight percent (8%) per annum from the date such amount was due until the same is paid in full.
  
 (mm) “Liquidation Event” means, whether in a single transaction or series of transactions, the voluntary or involuntary liquidation, dissolution or winding up of the Corporation or such Subsidiaries the assets of which constitute all or substantially all of the assets of the business of the Corporation and its Subsidiaries, taken as a whole.
  
 (nn) “Liquidation Funds” shall have the meaning given to it in Section 13 hereto.
  
 (oo) “Material Adverse Effect” means any material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Corporation and its Subsidiaries, if any, individually or taken as a whole, or on the transactions contemplated hereby or on the other Transaction Documents (as defined below), or by the agreements and instruments to be entered into in connection therewith or on the authority or ability of the Corporation to perform its obligations under the Transaction Documents.
  
 	 
	12
	

	 

  
 (pp) “Maximum Percentage” shall have the meaning given to it in Section 5 hereto.
  
 (qq) “New Issuance Price” shall have the meaning given to it in Section 8 hereto.
  
 (rr) “NRS” shall have the meaning given to it in the preamble hereto.
  
 (ss) “Options” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.
  
 (tt) “OTC Markets” means OTC Markets Group, Inc.
  
 (uu) “Parity Stock” shall have the meaning given to it in Section 3 hereto.
  
 (vv) “Person” means an individual, a limited liability Corporation, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof.
  
 (ww) “Primary Security” shall have the meaning given to it in Section 8 hereto.
  
 (xx) “Principal Market” means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, OTCPink, OTCQB, or OTCQX and any successor markets thereto.
  
 (yy) “Purchase Rights” shall have the meaning given to it in Section 7 hereto.
  
 (zz) “Register” shall have the meaning given to it in Section 5 hereto.
  
 (aaa) “Registered Series B” shall have the meaning given to it in Section 5 hereto.
  
 (bbb) “Required Dispute Documentation” shall have the meaning given to it in Section 22 hereto.
  
 (ccc) “Required Holders” shall have the meaning given to it in Section 3 hereto.
  
 (ddd) “Required Reserve Amount” shall have the meaning given to it in Section 11 hereto.
  
 (eee) “Reported Outstanding Share Number” shall have the meaning given to it in Section 5 hereto.
  
 (fff) “SEC” means the Securities and Exchange Commission or the successor thereto.
  
 	 
	13
	

	 

  
 (ggg) “Secondary Security” shall have the meaning given to it in Section 8 hereto.
  
 (hhh) “Senior Preferred Stock” shall have the meaning given to it in Section 3 hereto.
  
 (iii) “Series B” shall have the meaning given to it in Section 2 hereto.
  
 (jjj) “Series B Certificates” shall have the meaning given to it in Section 5 hereto.
  
 (kkk) “Share Delivery Deadline” shall have the meaning given to it in Section 5 hereto.
  
 (lll) “Stated Value” shall mean $1.30 per share, subject to adjustment for stock splits, stock dividends, recapitalizations, reorganizations, reclassifications, combinations, subdivisions or other similar events occurring after the Subscription Date with respect to the Common Stock.
  
 (mmm) “Subscription Date” with respect to any Holder means the date as of which both the Holder and the Corporation have executed the Exchange Agreement.
  
 (nnn) “Subsidiary” when used with respect to any Person, means any corporation or other organization, whether incorporated or unincorporated, of which (A) at least a majority of the securities or other interests having by their terms ordinary voting power to elect a majority of the board of directors or others performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such Person (through ownership of securities, by contract or otherwise) or (B) such Person or any subsidiary of such Person is a general partner of any general partnership or a manager of any limited liability company.
  
 (ooo) “Trading Day” means any day on which the Common Stock is eligible to be traded on the Principal Market or securities market on which the Common Stock is then traded, provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder.
  
 (ppp) “Transaction Documents” means the Exchange Agreement, this Certificate of Designations, and each of the other agreements and instruments entered into or delivered by the Corporation or any of the Holders in connection with the transactions contemplated by the Exchange Agreement, all as may be amended from time to time in accordance with the terms thereof.
  
 	 
	14
	

	 

  
 (qqq) “Transfer Agent” shall have the meaning given to it in Section 5 hereto.
  
 (rrr) “Triggering Event” shall have the meaning given to it in Section 6 hereto.
  
 (sss) “Triggering Event Conversion Amount” means 135% of the then Stated Value and Additional Amount, if any. 
  
 (ttt) “Triggering Event Conversion Date” shall have the meaning given to it in Section 5 hereto.
  
 (uuu) “Valuation Event” shall have the meaning given to it in Section 8 hereto.
  
 (vvv) “Variable Price” shall have the meaning given to it in Section 8 hereto.
  
 (www) “Variable Price Securities” shall have the meaning given to it in Section 8 hereto.
  
 (xxx) “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its functions of reporting prices, (b) if no volume weighted average price of the Common Stock is reported for the Trading Market, the highest reported price of the Common Stock on the Trading Day during the ten (10) Trading Days preceding such date, or (c) in all other cases, the fair market value of a share of Common Stock as determined by the Board of Directors of the Corporation.
  
 2. Designation and Number of Shares. There shall hereby be created and established a series of preferred stock of the Corporation designated as “Series B Convertible Preferred Stock” (the “Series B”). The authorized number of Series B shall be Two Million Six Hundred Ninety Four Thousand Five Hundred Fourteen (2,694,514) shares. Each share of Series B shall have a par value of $0.001. Capitalized terms not defined herein shall have the meaning as set forth in Section 1 above.
  
 3. Ranking. Except to the extent that the holders of at least a majority of the outstanding Series B which shall include Cavalry Fund I LP (“Cavalry”) as long as it owns at least 5% of the Series B (the “Required Holders”) expressly consent to the creation of Parity Stock (as defined below) or Senior Preferred Stock (as defined below) in accordance with Section 15, all shares of capital stock of the Corporation shall be junior in rank to all Series B with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (such junior stock is referred to herein collectively as “Junior Stock”). The rights of all such shares of capital stock of the Corporation shall be subject to the rights, powers, preferences and privileges of the Series B. Without limiting any other provision of this Certificate of Designations, without the prior express consent of the Required Holders, voting separate as a single class, the Corporation shall not hereafter authorize or issue any additional or other shares of capital stock that is (i) of senior rank to the Series B in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the “Senior Preferred Stock”), (ii) of pari passu rank to the Series B in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the “Parity Stock”) or (iii) any Junior Stock having a maturity date (or any other date requiring redemption or repayment of such shares of Junior Stock) that is prior to the date no Series B remain outstanding. Except as provided for herein, in the event of the merger or consolidation of the Corporation into another corporation, the Series B shall maintain their relative rights, powers, designations, privileges and preferences provided for herein for a period of at least two years following such merger or consolidation and no such merger or consolidation shall cause result inconsistent therewith.
   
 	 
	15
	

	 

  
 4. Dividends and Distributions.
  
 (a) Accrual and Payment of Dividends. From and after the Closing Date, cumulative dividends on each share of Series B shall accrue, on a quarterly basis in arrears, at the rate of 10% per annum on the Stated Value, plus the Additional Amount thereon. All accrued dividends on each share of Series B shall be paid upon conversion of the Series B for which the applicable dividend is due. At the option of the Corporation dividends may be paid in cash or shares of common stock. 
  
 (b) Participating Dividends. Each Holder of Series B shall be entitled to receive dividends or distributions on each share of Series B on an “as converted” into Common Stock basis as provided in Section 5 hereof when and if dividends are declared on the Common Stock by the Board of Directors. Dividends shall be paid in cash or property, as determined by the Board of Directors.
  
 5. Conversion. At any time after the Closing Date, each share of Series B shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock, on the terms and conditions set forth in this Section 5.
  
 (a) Holder’s Conversion Right. Subject to the provisions of Section 5(d), at any time or times on or after the Closing Date, each Holder shall be entitled to convert any portion of the outstanding Series B held by such Holder into validly issued, fully paid and non-assessable shares of Common Stock in accordance with Section 5(c) at the Conversion Rate (as defined below). The Corporation shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Corporation shall round such fraction of a share of Common Stock up to the nearest whole share. The Corporation shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including fees and expenses of the Transfer Agent (as defined below)) that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount (as defined below).
  
 	 
	16
	

	 

  
 (b) Conversion Rate. The number of shares of Common Stock issuable upon conversion of any share of Series B pursuant to Section 5(a) shall be determined by dividing (x) the Conversion Amount of such share of Series B by (y) the Conversion Price (the “Conversion Rate”):
  
 (i) “Conversion Amount” means, with respect to each share of Series B, as of the applicable date of determination, the sum of (1) the Stated Value thereof plus (2) the Additional Amount thereon and any accrued and unpaid Late Charges with respect to such Stated Value and Additional Amount as of such date of determination.
  
 (ii) “Conversion Price” means, with respect to each share of Series B, as of any Conversion Date or other date of determination, the lesser of: (i) $1.30 or (ii) 75% of the price paid per share by investors in any subsequent offering of the Corporation’s Common Stock or Common Stock equivalents, subject to adjustment as provided herein.
  
 (c) Mechanics of Conversion. The conversion of each share of Series B shall be conducted in the following manner:
  
 (i) Optional Conversion. To convert a share of Series B into shares of Common Stock on any date after the Closing Date (a “Conversion Date”), a Holder shall deliver (via, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion of the share(s) of Series B subject to such conversion in the form attached hereto as Exhibit I (the “Conversion Notice”) to the Corporation. If required by Section 5(c)(iii), within three Trading Days following a conversion of any such Series B as aforesaid, such Holder shall surrender to a nationally recognized overnight delivery service for delivery to the Corporation the original certificates representing the Series B (the “Series B Certificates”) so converted as aforesaid (or an indemnification undertaking with respect to the Series B in the case of its loss, theft or destruction as contemplated by Section 17). On or before the first Trading Day following the date of receipt of a Conversion Notice, the Corporation shall transmit by electronic mail an acknowledgment of confirmation, in the form attached hereto as Exhibit II, of receipt of such Conversion Notice to such Holder and the Corporation’s transfer agent (the “Transfer Agent”), which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the third Trading Day following the date of receipt of a Conversion Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the “Share Delivery Deadline”), the Corporation shall (1) provided that the Transfer Agent is participating in The Depository Trust Corporation’s (“DTC”) Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which such Holder shall be entitled to such Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, or (2) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable overnight courier) to the address as specified in such Conversion Notice, a certificate, registered in the name of such Holder or its designee, for the number of shares of Common Stock to which such Holder shall be entitled. If the number of Series B represented by the Series B Certificate(s) submitted for conversion pursuant to Section 5(c)(iii) is greater than the number of Series B being converted, then the Corporation shall, as soon as practicable and in no event later than three Trading Days after receipt of the Series B Certificate(s) and at its own expense, issue and deliver to such Holder (or its designee) a new Series B Certificate (in accordance with Section 17(d)) representing the number of Series B not converted. The Person or Persons entitled to receive the shares of Common Stock issuable upon a conversion of Series B shall be treated for all purposes as the record holder or holders of such shares of Common Stock on the Conversion Date.
   
 	 
	17
	

	 

  
 (ii) Corporation’s Failure to Timely Convert. If the Corporation shall fail, for any reason or for no reason, on or prior to the applicable Share Delivery Deadline, to issue to such Holder a certificate for the number of shares of Common Stock to which such Holder is entitled and register such shares of Common Stock on the Corporation’s share register or to credit such Holder’s or its designee’s balance account with DTC for such number of shares of Common Stock to which such Holder is entitled upon such Holder’s conversion of any Conversion Amount (as the case may be) (a “Conversion Failure”), then, in addition to all other remedies available to such Holder, (X) the Corporation shall pay in cash to such Holder on each day after the Share Delivery Deadline and during such Conversion Failure an amount equal to 2% of the product of (A) the sum of the number of shares of Common Stock not issued to such Holder on or prior to the Share Delivery Deadline and to which such Holder is entitled, multiplied by (B) the closing price of the Common Stock on the applicable Conversion Date and ending on the applicable Share Delivery Deadline, and (Y) such Holder, upon written notice to the Corporation, may void its Conversion Notice with respect to, and retain or have returned, as the case may be, all, or any portion, of such Series B that has not been converted pursuant to such Conversion Notice; provided that the voiding of a Conversion Notice shall not affect the Corporation’s obligations to make any payments which have accrued prior to the date of such notice pursuant to this Section 5(c)(ii) or otherwise. In addition to the foregoing, if on or prior to the Share Delivery Deadline the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, the Corporation shall fail to issue and deliver to such Holder (or its designee) a certificate and register such shares of Common Stock on the Corporation’s share register or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, the Transfer Agent shall fail to credit the balance account of such Holder or such Holder’s designee with DTC for the number of shares of Common Stock to which such Holder is entitled upon such Holder’s exercise hereunder or pursuant to the Corporation’s obligation pursuant to clause (II) below and if on or after such Share Delivery Deadline such Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock, issuable upon such conversion that such Holder so is entitled to receive from the Corporation, then, in addition to all other remedies available to such Holder, the Corporation shall, within three (3) Business Days after receipt of such Holder’s request and in such Holder’s discretion, either: (I) pay cash to such Holder in an amount equal to such Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including by any other Person in respect, or on behalf, of such Holder) (the “Buy-In Price”), at which point the Corporation’s obligation to so issue and deliver such certificate or credit such Holder’s balance account with DTC for the number of shares of Common Stock to which such Holder is entitled upon such Holder’s conversion hereunder (as the case may be) (and to issue such shares of Common Stock) shall terminate, or (II) promptly honor its obligation to so issue and deliver to such Holder a certificate or certificates representing such shares of Common Stock or credit such Holder’s balance account with DTC for the number of shares of Common Stock to which such Holder is entitled upon such Holder’s conversion hereunder (as the case may be) and pay cash to such Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (x) such number of shares of Common Stock multiplied by (y) the lowest Closing Sale Price of the Common Stock on any Trading Day during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (ii).
  
 	 
	18
	

	 

  
 (iii) Registration; Book-Entry. The Corporation shall maintain a register (the “Register”) for the recordation of the names and addresses of the Holders of each share of Series B and the Stated Value of the Series B (the “Registered Series B”). The entries in the Register shall be conclusive and binding for all purposes absent manifest error. The Corporation and each Holder of the Series B shall treat each Person whose name is recorded in the Register as the owner of a share of Series B for all purposes (including the right to receive payments and dividends hereunder) notwithstanding notice to the contrary. A Registered share of Series B may be assigned, transferred or sold only by registration of such assignment or sale on the Register. Upon its receipt of a written request to assign, transfer or sell one or more Registered Series B by such Holder thereof, the Corporation shall record the information contained therein in the Register and issue one or more new Registered Series B in the same aggregate Stated Value as the Stated Value of the surrendered Registered Series B to the designated assignee or transferee pursuant to Section 17, provided that if the Corporation does not so record an assignment, transfer or sale (as the case may be) of such Registered Series B within two Business Days of such a request, then the Register shall be automatically deemed updated to reflect such assignment, transfer or sale (as the case may be). Notwithstanding anything to the contrary set forth in this Section 5, following conversion of any Series B in accordance with the terms hereof, the applicable Holder shall not be required to physically surrender such Series B to the Corporation unless (A) the full or remaining number of Series B represented by the applicable Series B Certificate are being converted (in which event such certificate(s) shall be delivered to the Corporation as contemplated by this Section 5(c)(iii)) or (B) such Holder has provided the Corporation with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of Series B upon physical surrender of the applicable Series B Certificate. Each Holder and the Corporation shall maintain records showing the Stated Value, dividends and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to such Holder and the Corporation, so as not to require physical surrender of a Series B Certificate upon conversion. If the Corporation does not update the Register to record such Stated Value, dividends and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) within two (2) Business Days of such occurrence, then the Register shall be automatically deemed updated to reflect such occurrence. In the event of any dispute or discrepancy, such records of such Holder establishing the number of Series B to which the record holder is entitled shall be controlling and determinative in the absence of manifest error. A Holder and any transferee or assignee, by acceptance of a certificate, acknowledge and agree that, by reason of the provisions of this paragraph, following conversion of any Series B, the number of Series B represented by such certificate may be less than the number of Series B stated on the face thereof. Each Series B Certificate shall bear the following legend:
   
 	 
	19
	

	 

  
 ANY TRANSFEREE OR ASSIGNEE OF THIS CERTIFICATE SHOULD CAREFULLY REVIEW THE TERMS OF THE CORPORATION’S CERTIFICATE OF DESIGNATIONS RELATING TO THE SHARES OF SERIES B CONVERTIBLE PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE, INCLUDING SECTION 5(c)(iii) THEREOF. THE NUMBER OF SHARES OF SERIES B CONVERTIBLE PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE MAY BE LESS THAN THE NUMBER OF SHARES OF SERIES B CONVERTIBLE PREFERRED STOCK STATED ONTHE FACE HEREOF PURSUANT TO SECTION 5(c)(iii) OF THE CERTIFICATE OF DESIGNATIONS RELATING TO THE SHARES OF SERIES B CONVERTIBLE PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE.
  
 (iv) Pro Rata Conversion; Disputes. In the event that the Corporation receives a Conversion Notice from more than one Holder for the same Conversion Date and the Corporation can convert some, but not all, of such Series B submitted for conversion, the Corporation shall convert from each Holder electing to have Series B converted on such date a pro rata amount of such Holder’s Series B submitted for conversion on such date based on the number of Series B submitted for conversion on such date by such Holder relative to the aggregate number of Series B submitted for conversion on such date. In the event of a dispute as to the number of shares of Common Stock issuable to a Holder in connection with a conversion of Series B, the Corporation shall issue to such Holder the number of shares of Common Stock not in dispute and resolve such dispute in accordance with Section 22.
  
 	 
	20
	

	 

  
 (d) Limitation on Beneficial Ownership. The Corporation shall not effect the conversion of any of the Series B held by a Holder, and such Holder shall not have the right to convert any of the Series B held by such Holder pursuant to the terms and conditions of this Certificate of Designations and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, such Holder would beneficially own in excess of 4.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such conversion (which provision may be waived by such Holder by written notice from such Holder to the Corporation, which notice shall be effective 61 calendar days after the date of such notice). For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder shall include the number of shares of Common Stock held by such Holder plus the number of shares of Common Stock issuable upon conversion of the Series B with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) conversion of the remaining, nonconverted Series B beneficially owned by such Holder and (B) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Corporation (including any convertible notes, convertible preferred stock or warrants) beneficially owned by such Holder subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 5(d). For purposes of this Section 5(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934 Act. For purposes of determining the number of outstanding shares of Common Stock a Holder may acquire upon the conversion of such Series B without exceeding the Maximum Percentage, such Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Corporation’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Corporation or (z) any other written notice by the Corporation or the Transfer Agent, if any, setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”). If the Corporation receives a Conversion Notice from a Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Corporation shall notify such Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause such Holder’s beneficial ownership, as determined pursuant to this Section 5(d), to exceed the Maximum Percentage, such Holder must notify the Corporation of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion Notice. For any reason at any time, upon the written or oral request of any Holder, the Corporation shall within one (1) Business Day confirm orally and in writing or by electronic mail to such Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Corporation, including such Series B, by such Holder since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to a Holder upon conversion of such Series B results in such Holder being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which such Holder’s beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and such Holder shall not have the power to vote or to transfer the Excess Shares. For purposes of clarity, the shares of Common Stock issuable to a Holder pursuant to the terms of this Certificate of Designations in excess of the Maximum Percentage shall not be deemed to be beneficially owned by such Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to convert such Series B pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 5(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 5(d) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The provisions of this Section 5(d) shall be of no further force or effect if the Holder participates in a subsequent transaction with the Corporation which results in the Holder beneficially owning in excess of 4.99% of the number of shares of the Common Stock outstanding which shall include securities convertible into Common Stock which do not contain a beneficial ownership limitation.
  
 	 
	21
	

	 

  
 (e) Triggering Event Conversion. Subject to Section 5(d), at any time during the period commencing on the date of the occurrence of a Triggering Event (defined below in Section 6 (a)) and ending on the earlier to occur of (x) the date of the cure of such Triggering Event and (y) twenty (20) Trading Days after the date the Corporation delivers written notice to the Holder of such Triggering Event, a Holder may, at such Holder’s option, by delivery of a Conversion Notice to the Corporation (the date of any such Conversion Notice, each an “Triggering Event Conversion Date”), convert all, or any number of Series B (such Conversion Amount of the Series B to be converted pursuant to this Section 5(e), the Triggering Event Conversion Amount into shares of Common Stock at the Conversion Price (each, a “Triggering Event Conversion”).
  
 6. Triggering Event.
  
 (a) Triggering Event. Each of the following events shall constitute a “Triggering Event”:
  
 	 
	22
	

	 

  
 (i) the Corporation does not meet the current public information requirements under Rule 144 in respect of the shares of Common Stock issuable upon conversion of the Series B;
  
 (ii) the suspension from trading or failure of the Common Stock to be trading or listed (as applicable) on a Principal Market for a period of five consecutive Trading Days;
  
 (iii) the Corporation’s notice, written or oral, to any holder of Series B, including, without limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any Series B into shares of Common Stock that is requested in accordance with the provisions of this Certificate of Designations, other than pursuant to Section 5(d) hereof;
  
 (iv) at any time following the tenth consecutive day that a Holder’s Authorized Share Allocation (as defined in Section 11 below) is less than 125% of the number of shares of Common Stock that such Holder would be entitled to receive upon a conversion, in full, of all of the Series B then held by such Holder (without regard to any limitations on conversion set forth in this Certificate of Designations);
  
 (v) the Board of Directors fails to declare any dividend to be paid on the applicable dividend date in accordance with Section 4;
  
 (vi) the Corporation’s failure to pay to any Holder any dividend on any dividend date (whether or not declared by the Board) or any other amount when and as due under this Certificate of Designations (including, without limitation, the Corporation’s failure to pay any amounts hereunder), the Exchange Agreement or any other Transaction Document or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby (in each case, whether or not permitted pursuant to the NRS), except, in the case of a failure to pay dividends and Late Charges when and as due, in each such case only if such failure remains uncured for a period of at least two Trading Days;
  
 (vii) the Corporation, on two or more occasions, either (A) fails to cure a Conversion Failure by delivery of the required number of shares of Common Stock within five Trading Days after the applicable Conversion Date or (B) fails to remove any restrictive legend on any certificate or any shares of Common Stock issued to such Holder upon conversion of any Series B or as and when required by this Certificate of Designations unless otherwise then prohibited by applicable federal securities laws, and any such failure remains uncured for at least five Trading Days;
  
 	 
	23
	

	 

  
 (viii) the occurrence of any default under, redemption of or acceleration prior to maturity of at least an aggregate of $100,000 of indebtedness of the Corporation or any of its Subsidiaries;
  
 (ix) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be instituted by or against the Corporation or any Subsidiary and, if instituted against the Corporation or any Subsidiary by a third party, shall not be dismissed within thirty (30) days of their initiation;
  
 (x) the commencement by the Corporation or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of the Corporation or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Corporation or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the Corporation or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law;
  
 (xi) the entry by a court of (i) a decree, order, judgment or other similar document in respect of the Corporation or any Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii) a decree, order, judgment or other similar document adjudging the Corporation or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Corporation or any Subsidiary under any applicable federal, state or foreign law or (iii) a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Corporation or any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for a period of 30 consecutive days;
  
 	 
	24
	

	 

  
 (xii) a final judgment or judgments for the payment of money aggregating in excess of $100,000 are rendered against the Corporation and/or any of its Subsidiaries and which judgments are not, within 30 days after the entry thereof, bonded, discharged, settled or stayed pending appeal, or are not discharged within 30 days after the expiration of such stay; provided, however, any judgment which is covered by insurance or an indemnity from a credit worthy party shall not be included in calculating the $100,000 amount set forth above so long as the Corporation provides each Holder a written statement from such insurer or indemnity provider (which written statement shall be reasonably satisfactory to each Holder) to the effect that such judgment is covered by insurance or an indemnity and the Corporation or such Subsidiary (as the case may be) will receive the proceeds of such insurance or indemnity within 30 days of the issuance of such judgment;
  
 (xiii) the Corporation and/or any Subsidiary, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period, any payment with respect to any Indebtedness in excess of $100,000 due to any third party (other than, with respect to unsecured Indebtedness only, payments contested by the Corporation and/or such Subsidiary (as the case may be) in good faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $100,000, which breach or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffer to exist any other circumstance or event that would, with or without the passage of time or the giving of notice, result in a default or event of default under any agreement binding the Corporation or any Subsidiary, which default or event of default would or is likely to have a material adverse effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition) or prospects of the Corporation or any of its Subsidiaries, individually or in the aggregate;
  
 (xiv) other than as specifically set forth in another clause of this Section 6(a), the Corporation or any Subsidiary breaches any representation or warranty in any material respect (other than representations or warranties subject to material adverse effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction Document, except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains uncured for a period of two consecutive Trading Days;
  
 (xv) a false or inaccurate certification (including a false or inaccurate deemed certification) by the Corporation as to whether any Triggering Event has occurred;
  
 (xvi) changes its Transfer Agent;
   
 	 
	25
	

	 

  
 (xvii) any Material Adverse Effect occurs; or
  
 (xiii) any provision of any Transaction Document shall at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested, directly or indirectly, by the Corporation or any Subsidiary, or a proceeding shall be commenced by the Corporation or any Subsidiary or any governmental authority having jurisdiction over any of them, seeking to establish the invalidity or unenforceability thereof or the Corporation or any of its Subsidiaries shall deny in writing that it has any liability or obligation purported to be created under one or more Transaction Documents.
  
 (b) Notice of a Triggering Event. Upon the occurrence of a Triggering Event with respect to the Series B, the Corporation shall within one Business Day deliver written notice thereof via facsimile or electronic mail and overnight courier (with next day delivery specified) to each Holder.
  
 7. Rights Upon Issuance of Purchase Rights and Other Corporate Events.
  
 (a) Purchase Rights. In addition to any adjustments pursuant to Section 8 and 9 below, if at any time the Corporation grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Purchase Rights”), then each Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such Holder could have acquired if such Holder had held the number of shares of Common Stock acquirable upon complete conversion of all the Series B (without taking into account any limitations or restrictions on the convertibility of the Series B) held by such Holder immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that such Holder’s right to participate in any such Purchase Right would result in such Holder exceeding the Maximum Percentage, then such Holder shall not be entitled to participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such extent shall be held in abeyance for such Holder until such time or times, if ever, as its right thereto would not result in such Holder exceeding the Maximum Percentage), at which time or times such Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation.
  
 	 
	26
	

	 

  
 (b) Other Corporate Events. In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “Corporate Event”), the Corporation shall make appropriate provision to insure that each Holder will thereafter have the right to receive upon a conversion of all the Series B held by such Holder (i) in addition to the shares of Common Stock receivable upon such conversion, such securities or other assets to which such Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by such Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of the Series B contained in this Certificate of Designations) or (ii) in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as such Holder would have been entitled to receive had the Series B held by such Holder initially been issued with conversion rights for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. The provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section 7 shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion of the Series B contained in this Certificate of Designations. “Fundamental Transaction” means the occurrence of the Corporation (i) directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (A) consolidating or merging with or into (whether or not the Corporation is the surviving corporation) another Person, (B) selling, assigning, transferring, conveying or otherwise disposing of all or substantially all of the properties or assets of the Corporation or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to one or more Persons, (C) making, or allowing one or more Persons to make, or allowing the Corporation to be subject to or have its Common Stock be subject to or party to one or more Persons making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Persons making or party to, or Affiliated with any Persons making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of shares of Common Stock such that all Persons making or party to, or Affiliated with any Person making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, (D) consummating a stock or share purchase agreement or other business combination (including a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Persons whereby all such Persons, individually or in the aggregate, acquire, either (x) at least 50% of the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all the Persons making or party to, or Affiliated with any Persons making or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock such that the Persons become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (E) reorganize, recapitalize or reclassify its Common Stock.
  
 	 
	27
	

	 

  
 8. Rights Upon Issuance of Other Securities.
  
 (a) Adjustment of Conversion Price upon Issuance of Common Stock. If on or after the Subscription Date the Corporation issues or sells, or in accordance with this Section 8(a) is deemed to have issued or sold, any shares of Common Stock, including the issuance or sale of shares of Common Stock owned or held by or for the account of the Corporation, but excluding any Excluded Securities (issued or sold or deemed to have been issued or sold) for a consideration per share (the “New Issuance Price”) less than a price equal to the Conversion Price in effect immediately prior to such issue or sale or deemed issuance or sale (such Conversion Price then in effect is referred to herein as the “Applicable Price”) (the foregoing a “Dilutive Issuance”), then, immediately after such Dilutive Issuance, the Conversion Price then in effect shall be reduced to the New Issuance Price. For all purposes of the foregoing (including determining the adjusted Conversion Price and the New Issuance Price under this Section 8(a), the following shall be applicable:
  
 (i) Issuance of Options. If the Corporation in any manner grants or sells any Options and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Corporation at the time of the granting or sale of such Option for such price per share. For purposes of this Section 8(a)(i), the “lowest price per share for which one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof” shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Corporation with respect to any one share of Common Stock upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person). Except as contemplated below, no further adjustment of the Conversion Price shall be made upon the actual issuance of such share of Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms thereof or upon the actual issuance of such share of Common Stock upon conversion, exercise or exchange of such Convertible Securities.
  
 	 
	28
	

	 

  
 (ii) Issuance of Convertible Securities. If the Corporation in any manner issues or sells any Convertible Securities and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Corporation at the time of the issuance or sale of such Convertible Securities for such price per share. For purposes of this Section 8(a)(ii), the “lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof” shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received or receivable by the Corporation with respect to one share of Common Stock upon the issuance or sale of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof and (y) the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable upon conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such Convertible Security (or any other Person) upon the issuance or sale of such Convertible Security plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except as contemplated below, no further adjustment of the Conversion Price shall be made upon the actual issuance of such share of Common Stock upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issue or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of the Conversion Price has been or is to be made pursuant to other provisions of this Section 8(a), except as contemplated below, no further adjustment of the Conversion Price shall be made by reason of such issue or sale.
  
 (iii) Change in Option Price or Rate of Conversion. If the purchase or exercise price provided for in any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time, the Conversion Price in effect at the time of such increase or decrease shall be adjusted to the Conversion Price which would have been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional consideration or increased or decreased conversion rate (as the case may be) at the time initially granted, issued or sold. For purposes of this Section 8(a)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Subscription Date are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section 8(a)(iii) shall be made if such adjustment would result in an increase of the Conversion Price then in effect.
   
 	 
	29
	

	 

  
 (iv) Calculation of Consideration Received. If any Option and/or Convertible Security is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Corporation (as determined by the Required Holders, the “Primary Security”, and such Option and/or Convertible Security, the “Secondary Securities”), together comprising one integrated transaction (or one or more transactions if such issuances or sales or deemed issuances or sales of securities of the Corporation either (A) have at least one investor or purchaser in common, (B) are consummated in reasonable proximity to each other and/or (C) are consummated under the same plan of financing), the consideration per share of Common Stock with respect to such Primary Security shall be deemed to be equal to the difference of (x) the lowest price per share for which one share of Common Stock was issued in such integrated transaction (or was deemed to be issued pursuant to Section 8(a)(i) or 8(a)(ii) above, as applicable) solely with respect to such Primary Security, minus (y) with respect to such Secondary Securities, the sum of (A) the Consideration Value of each such Option, if any, (B) the fair market value (as determined by the Required Holders in good faith) or the Consideration Value, as applicable, and (C) the fair market value (as determined by the Required Holder) of such Convertible Security, if any, in each case, as determined on a per share basis in accordance with this Section 8(a)(iv). If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security) will be deemed to be the net amount of consideration received by the Corporation therefor. If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security), the amount of such consideration received by the Corporation will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Corporation for such securities will be the average VWAP of such security for the five Trading Day period immediately preceding the date of receipt. The fair value of any consideration other than cash or publicly traded securities will be determined jointly by the Corporation and the Required Holders. If such parties are unable to reach agreement within 10 days after the occurrence of an event requiring valuation (the “Valuation Event”), the fair value of such consideration will be determined within five Trading Days after the tenth day following such Valuation Event by an independent, reputable appraiser jointly selected by the Corporation and the Required Holders. The determination of such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Holders.
  
 	 
	30
	

	 

  
 (v) Record Date. If the Corporation takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).
  
 (b) Holder’s Right of Adjusted Conversion Price. In addition to and not in limitation of the other provisions of this Section 8(b) or the Exchange Agreement, if the Corporation in any manner issues or sells or enters into any agreement to issue or sell, any Common Stock, Options or Convertible Securities (any such securities, “Variable Price Securities”) that are issuable pursuant to such agreement or convertible into or exchangeable or exercisable for shares of Common Stock pursuant to such Options or Convertible Securities, as applicable, at a price which varies with the market price of the shares of Common Stock (the “Variable Price”), the Corporation shall provide written notice thereof via (i) electronic mail or (ii) overnight courier to each Holder on the date of such agreement and/or the issuance of such shares of Common Stock, Convertible Securities or Options, as applicable. From and after the date the Corporation enters into such agreement or issues any such Variable Price Securities, each Holder shall have the right, but not the obligation, in its sole discretion to substitute the Variable Price for the Conversion Price upon conversion of the Series B by designating in the Conversion Notice delivered upon any conversion of Series B that solely for purposes of such conversion such Holder is relying on the Variable Price rather than the Conversion Price then in effect. A Holder’s election to rely on a Variable Price for a particular conversion of Series B shall not obligate such Holder to rely on a Variable Price for any future conversions of Series B; provided; further, that the provisions of this Section 8(b) shall not apply to any Excluded Securities.
  
 (c) Calculations. All calculations under this Section 8 shall be made by rounding to the nearest cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Corporation, and the disposition of any such shares shall be considered an issue or sale of Common Stock.
  
 (d) Voluntary Adjustment by Corporation. The Corporation may at any time while any Series B remain outstanding, with the prior consent of the Required Holders, reduce the then current Conversion Price to any amount and for any period of time deemed appropriate by the Board of Directors.
  
 (e) Excluded Securities. No adjustments contained in this Section 8 shall be made upon the sale or issuance of any Excluded Securities sold or deemed to have been sold.
   
 	 
	31
	

	 

    
 9. Adjustment of Conversion Price upon Subdivision or Combination of Common Stock. Without limiting any provision of Section 8(a), if the Corporation at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. Without limiting any provision of Section 8(a), if the Corporation at any time on or after the Subscription Date combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section 9 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this Section 9 occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event.
  
 10. Noncircumvention. The Corporation hereby covenants and agrees that the Corporation will not, by amendment of its Certificate of Incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Certificate of Designations, and will at all times in good faith carry out all the provisions of this Certificate of Designations and take all action as may be required to protect the rights of the Holders. Without limiting the generality of the foregoing or any other provision of this Certificate of Designations or the other Transaction Documents, the Corporation (a) shall not increase the par value of any shares of Common Stock receivable upon the conversion of any Series B above the Conversion Price then in effect, (b) shall take all such actions as may be necessary or appropriate in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock upon the conversion of Series B and (c) shall, so long as any Series B are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the conversion of the Series B, the maximum number of shares of Common Stock as shall from time to time be necessary to effect the conversion of the Series B then outstanding (without regard to any limitations on conversion contained herein).
  
 11. Authorized Shares.
  
 (a) Reservation. So long as any Series B remain outstanding, the Corporation shall at all times reserve at least 125% times the number of shares of Common Stock as shall from time to time be necessary to effect the conversion of all of the Series B then outstanding (without regard to any limitations on conversions) (the “Required Reserve Amount”). The Required Reserve Amount (including each increase in the number of shares so reserved) shall be allocated pro rata among the Holders based on the number of the Series B held by each Holder on the Subscription Date or increase in the number of reserved shares, as the case may be (the “Authorized Share Allocation”). In the event that a Holder shall sell or otherwise transfer any of such Holder’s Series B, each transferee shall be allocated a pro rata portion of such Holder’s Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which ceases to hold any Series B shall be allocated to the remaining Holders of Series B, pro rata based on the number of the Series B then held by the Holders.
  
 	 
	32
	

	 

  
 (b) Insufficient Authorized Shares. If, notwithstanding Section 11(a) and not in limitation thereof, while any of the Series B remain outstanding the Corporation does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon conversion of the Series B at least a number of shares of Common Stock equal to the Required Reserve Amount (an “Authorized Share Failure”), then the Corporation shall immediately take all action necessary to increase the Corporation’s authorized shares of Common Stock to an amount sufficient to allow the Corporation to reserve the Required Reserve Amount for the Series B then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than 90 days after the occurrence of such Authorized Share Failure, the Corporation shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Corporation shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its Board of Directors to recommend to the stockholders that they approve such proposal. In lieu of a meeting of stockholders, the Corporation may effect such action by written consent in accordance with Section 14(c) of the 1934 Act. Except as provided in the first sentence of Section 11(a), in the event that the Corporation is prohibited from issuing shares of Common Stock to a Holder upon any conversion due to the failure by the Corporation to have sufficient shares of Common Stock available out of the authorized but unissued shares of Common Stock (such unavailable number of shares of Common Stock, the “Authorized Failure Shares”), in lieu of delivering such Authorized Failure Shares to such Holder, the Corporation shall pay cash in exchange for the redemption of such portion of the Conversion Amount convertible into such Authorized Failure Shares at a price equal to the sum of (i) the product of (x) such number of Authorized Failure Shares and (y) the average Closing Sale Prices of the Common Stock on the Trading Days during the period commencing on the date such Holder delivers the applicable Conversion Notice with respect to such Authorized Failure Shares to the Corporation and ending on the date of such issuance under this Section 11(b). Nothing contained in this Section shall limit any obligations of the Corporation under any provision of the Exchange Agreement.
  
 12. Voting Rights. Subject to Section 5(d) and the Maximum Percentage, each Holder shall be entitled to the whole number of votes equal to the number of shares of Common Stock into which such holder’s Series B would be convertible on the record date for the vote or consent of stockholders, and shall otherwise have voting rights and powers equal to the voting rights and powers of the Common Stock. To the extent that under the NRS the vote of the holders of the Series B, voting separately as a class or series as applicable, is required to authorize a given action of the Corporation, the affirmative vote or consent of the holders of all of the shares of the Series B, voting together in the aggregate and not in separate series unless required under the NRS, represented at a duly held meeting at which a quorum is presented or by written consent of the Required Holders (except as otherwise may be required under the NRS), voting together in the aggregate and not in separate series unless required under the NRS, shall constitute the approval of such action by both the class or the series, as applicable. Subject to Section 5(d), to the extent that under the NRS holders of the Series B are entitled to vote on a matter with holders of shares of Common Stock, voting together as one class, each share of Series B shall entitle the holder thereof to cast that number of votes per share as is equal to the number of shares of Common Stock into which it is then convertible (subject to the ownership limitations specified in Section 5(d) hereof and the Maximum Percentage) using the record date for determining the stockholders of the Corporation eligible to vote on such matters as the date as of which the Conversion Price is calculated. Holders of the Series B shall be entitled to written notice of all stockholder meetings or written consents (and copies of proxy materials and other information sent to stockholders) with respect to which they would be entitled by vote, which notice would be provided pursuant to the Corporation’s bylaws and the NRS.
   
 	 
	33
	

	 

  
 13. Liquidation, Dissolution, Winding-Up. In the event of a Liquidation Event, the Holders shall be entitled to receive in cash out of the assets of the Corporation, whether from capital or from earnings available for distribution to its stockholders (the “Liquidation Funds”), before any amount shall be paid to the holders of any of shares of Junior Stock, but pari passu with any Parity Stock then outstanding, an amount per share of Series B equal to the greater of (A) the Conversion Amount thereof on the date of such payment and (B) the amount per share such Holder would receive if such Holder converted such Series B into Common Stock immediately prior to the date of such payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the Holders and holders of shares of Parity Stock, then each Holder and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of Liquidation Funds payable to such Holder and such holder of Parity Stock as a liquidation preference, in accordance with their respective certificate of designations (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series B and all holders of shares of Parity Stock. To the extent necessary, the Corporation shall cause such actions to be taken by each of its Subsidiaries so as to enable, to the maximum extent permitted by law, the proceeds of a Liquidation Event to be distributed to the Holders in accordance with this Section. All the preferential amounts to be paid to the Holders under this Section shall be paid or set apart for payment before the payment or setting apart for payment of any amount for, or the distribution of any Liquidation Funds of the Corporation to the holders of shares of Junior Stock in connection with a Liquidation Event as to which this Section applies.
  
 14. Distribution of Assets. In addition to any adjustments pursuant to Section 8 and 9, if the Corporation shall declare or make any dividend or other distributions of its assets (or rights to acquire its assets) to any or all holders of shares of Common Stock, by way of return of capital or otherwise (including any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (the “Distributions”), then each Holder, as holders of Series B, will be entitled to such Distributions as if such Holder had held the number of shares of Common Stock acquirable upon complete conversion of the Series B (without taking into account any limitations or restrictions on the convertibility of the Series B) immediately prior to the date on which a record is taken for such Distribution or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for such Distributions (provided, however, that to the extent that such Holder’s right to participate in any such Distribution would result in such Holder exceeding the Maximum Percentage, then such Holder shall not be entitled to participate in such Distribution to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to the extent of any such excess) and the portion of such Distribution shall be held in abeyance for such Holder until such time or times as its right thereto would not result in such Holder exceeding the Maximum Percentage, at which time or times, if any, such Holder shall be granted such rights (and any rights under this Section 14 on such initial rights or on any subsequent such rights to be held similarly in abeyance) to the same extent as if there had been no such limitation).
  
 	 
	34
	

	 

  
 15. Vote to Change the Terms of or Issue Series B. Except as may be provided for in the Exchange Agreement, and in addition to any other rights provided by law, except where the vote or written consent of the holders of a greater number of shares is required by law or by another provision of the Certificate of Incorporation, without first obtaining the affirmative vote at a meeting duly called for such purpose or the written consent without a meeting of the Required Holders, voting together as a single class, the Corporation shall not: (a) amend or repeal any provision of, or add any provision to, its Certificate of Incorporation or bylaws, or file any certificate of designations or certificate of amendment of any series of shares of preferred stock, if such action would adversely alter or change in any respect the preferences, rights, privileges or powers, or restrictions provided for the benefit, of the Series B, regardless of whether any such action shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation or otherwise; (b) increase or decrease (other than by conversion) the authorized number of Series B; (c) without limiting any provision of Section 2, create or authorize (by reclassification or otherwise) any new class or series of shares that has a preference over or is on a parity with the Series B with respect to dividends or the distribution of assets on the liquidation, dissolution or winding up of the Corporation; (d) purchase, repurchase or redeem any shares of capital stock of the Corporation junior in rank to the Series B (other than pursuant to equity incentive agreements (that have in good faith been approved by the Board of Directors) with employees giving the Corporation the right to repurchase shares upon the termination of services); (e) without limiting any provision of Section 2, pay dividends or make any other distribution on any shares of any capital stock of the Corporation junior in rank to the Series B; (f) issue any Series B or preferred stock other than as provided in Section 2; (g) until the one year anniversary of the Closing Date, enter into (i) any mortgage, credit agreement or other facility, indenture agreement, factoring agreement or other instrument, under which there may be issued, or by which there may be secured or evidenced, any indebtedness for borrowed money or money due that involves, either individually or in aggregate with other such agreements, obligations greater than $25,000.00, and (ii) any equipment lease, agreement evidencing purchase money security interests, or other similar transaction in the ordinary course of business that involves, either individually or in aggregate with other such agreements, obligations greater than $25,000.00 or (h) without limiting any provision of Section 8 and 9, whether or not prohibited by the terms of the Series B, circumvent a right of the Series B.
  
 16. Transfer of Series B. A Holder may transfer some or all of its Series B without the consent of the Corporation, subject to compliance with Section 5 of the Securities Act of 1933.
  
 17. Reissuance of Preferred Certificates.
  
 	 
	35
	

	 

  
 (a) Transfer. If any Series B are to be transferred, the applicable Holder shall surrender the applicable Series B Certificate to the Corporation, whereupon the Corporation will forthwith issue and deliver upon the order of such Holder a new Series B Certificate (in accordance with Section 17(d)), registered as such Holder may request, representing the outstanding number of Series B being transferred by such Holder and, if less than the entire outstanding number of Series B is being transferred, a new Series B Certificate (in accordance with Section 17(d)) to such Holder representing the outstanding number of Series B not being transferred. Such Holder and any assignee, by acceptance of the Series B Certificate, acknowledge and agree that, by reason of the provisions of Section 5(c)(i) following conversion of any of the Series B, the outstanding number of Series B represented by the Series B may be less than the number of Series B stated on the face of the Series B.
  
 (b) Lost, Stolen or Mutilated Series B Certificate. Upon receipt by the Corporation of evidence reasonably satisfactory to the Corporation of the loss, theft, destruction or mutilation of a Series B Certificate (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the applicable Holder to the Corporation in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of such Series B Certificate, the Corporation shall execute and deliver to such Holder a new Series B Certificate (in accordance with Section 17(d)) representing the applicable outstanding number of Series B.
  
 (c) Series B Certificate Exchangeable for Different Denominations. Each Series B Certificate is exchangeable, upon the surrender hereof by the applicable Holder at the principal office of the Corporation, for a new Series B Certificate or Series B Certificate(s) (in accordance with Section 17(d)) representing in the aggregate the outstanding number of the Series B in the original Series B Certificate, and each such new certificate will represent such portion of such outstanding number of Series B from the original Series B Certificate as is designated by such Holder at the time of such surrender.
  
 (d) Issuance of New Series B Certificate. Whenever the Corporation is required to issue a new Series B Certificate pursuant to the terms of this Certificate of Designations, such new Series B Certificate (i) shall represent, as indicated on the face of such Series B Certificate, the number of Series B remaining outstanding (or in the case of a new Series B Certificate being issued pursuant to Section 17(a) or Section 17(c), the number of Series B designated by such Holder which, when added to the number of Series B represented by the other new Series B Certificates issued in connection with such issuance, does not exceed the number of Series B remaining outstanding under the original Series B Certificate immediately prior to such issuance of new Series B Certificate), and (ii) shall have an issuance date, as indicated on the face of such new Series B Certificate, which is the same as the issuance date of the original Series B Certificate.
  
 	 
	36
	

	 

  
 18. Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Certificate of Designations shall be cumulative and in addition to all other remedies available under this Certificate of Designations and any of the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit any Holder’s right to pursue actual and consequential damages for any failure by the Corporation to comply with the terms of this Certificate of Designations. The Corporation covenants to each Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by a Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Corporation (or the performance thereof). The Corporation acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holders and that the remedy at law for any such breach may be inadequate. The Corporation therefore agrees that, in the event of any such breach or threatened breach, each Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Corporation shall provide all information and documentation to a Holder that is requested by such Holder to enable such Holder to confirm the Corporation’s compliance with the terms and conditions of this Certificate of Designations.
  
 19. Payment of Collection, Enforcement and Other Costs. If (a) any Series B are placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding or a Holder otherwise takes action to collect amounts due under this Certificate of Designations with respect to the Series B or to enforce the provisions of this Certificate of Designations or (b) there occurs any bankruptcy, reorganization, receivership of the Corporation or other proceedings affecting Corporation creditors’ rights and involving a claim under this Certificate of Designations, then the Corporation shall pay the costs incurred by such Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including attorneys’ fees and disbursements.
  
 20. Construction; Headings. This Certificate of Designations shall be deemed to be jointly drafted by the Corporation and the Holders and shall not be construed against any such Person as the drafter hereof. The headings of this Certificate of Designations are for convenience of reference and shall not form part of, or affect the interpretation of, this Certificate of Designations. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Certificate of Designations instead of just the provision in which they are found. Unless expressly indicated otherwise, all section references are to sections of this Certificate of Designations. Terms used in this Certificate of Designations and not otherwise defined herein, but defined in the other Transaction Documents, shall have the meanings ascribed to such terms on the Closing Date in such other Transaction Documents unless otherwise consented to in writing by the Required Holders.
  
 21. Failure or Indulgence Not Waiver. No failure or delay on the part of a Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. This Certificate of Designations shall be deemed to be jointly drafted by the Corporation and all Holders and shall not be construed against any Person as the drafter hereof. Notwithstanding the foregoing, nothing contained in this Section 21 shall permit any waiver of any provision of Section 19.
  
 	 
	37
	

	 

  
 22. Dispute Resolution.
  
 (a) Submission to Dispute Resolution.
  
 (i) In the case of a dispute relating to the Closing Sale Price, a Conversion Price, a VWAP or a fair market value or the arithmetic calculation of a Conversion Rate, (including a dispute relating to the determination of any of the foregoing), the Corporation or the applicable Holder (as the case may be) shall submit the dispute to the other party via electronic mail (A) if by the Corporation, within two Business Days after the occurrence of the circumstances giving rise to such dispute or (B) if by such Holder at any time after such Holder learned of the circumstances giving rise to such dispute. If such Holder and the Corporation are unable to promptly resolve such dispute relating to such closing bid price, such Closing Sale Price, such Conversion Price, such VWAP or such fair market value, or the arithmetic calculation of such Conversion Rate, at any time after the second Business Day following such initial notice by the Corporation or such Holder (as the case may be) of such dispute to the Corporation or such Holder (as the case may be), then such Holder may, at its sole option, select an independent, reputable investment bank to resolve such dispute.
  
 (ii) Such Holder and the Corporation shall each deliver to such investment bank (A) a copy of the initial dispute submission so delivered in accordance with the first sentence of this Section 22(a) and (B) written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth Business Day immediately following the date on which such Holder selected such investment bank (the “Dispute Submission Deadline”) (the documents referred to in the immediately preceding clauses (A) and (B) are collectively referred to herein as the “Required Dispute Documentation”) (it being understood and agreed that if either such Holder or the Corporation fails to so deliver all of the Required Dispute Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to) deliver or submit any written documentation or other support to such investment bank with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such investment bank prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Corporation and such Holder or otherwise requested by such investment bank, neither the Corporation nor such Holder shall be entitled to deliver or submit any written documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation).
  
 	 
	38
	

	 

  
 (iii) The Corporation and such Holder shall cause such investment bank to determine the resolution of such dispute and notify the Corporation and such Holder of such resolution no later than 10 Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be borne solely by the Corporation, and such investment bank’s resolution of such dispute shall be final and binding upon all parties absent manifest error.
  
 (b) Arbitration. Except for a claim for equitable relief, any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application, implementation, breach or enforcement which the parties are unable to resolve by mutual agreement, shall be settled by submission by either party of the controversy, claim or dispute to binding arbitration in New York County, New York (unless the parties agree in writing to a different location), before one arbitrator in accordance with the rules of the American Arbitration Association then in effect. In any such arbitration proceeding, the parties agree to provide all discovery deemed necessary by the arbitrator. The decision and award made by the arbitrator shall be final, binding and conclusive on all parties hereto for all purposes, and judgment may be entered thereon in any court having jurisdiction thereof. Any arbitration proceeding brought under this Agreement shall be subject to all statutes of limitation in the same manner as if an action were filed in a court.
  
 23. Notices. The Corporation shall provide each Holder of Series B with prompt written notice of all actions taken pursuant to the terms of this Certificate of Designations, including in reasonable detail a description of such action and the reason therefor. Whenever notice is required to be given under this Certificate of Designations, unless otherwise provided herein, such notice must be in writing and shall be given in accordance with Section 6.3 of the Exchange Agreement. The Corporation shall provide each Holder with prompt written notice of all actions taken pursuant to this Certificate of Designations, including in reasonable detail a description of such action and the reason therefore. Without limiting the generality of the foregoing, the Corporation shall give written notice to each Holder (i) immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least 15 days prior to the date on which the Corporation closes its books or takes a record (A) with respect to any dividend or distribution upon the Common Stock, (B) with respect to any grant, issuances, or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to such Holder.
  
 	 
	39
	

	 

  
 24. Governing Law; Exclusive Jurisdiction. This Certificate of Designations shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Certificate of Designations shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Nevada or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Except as otherwise required by this Certificate of Designations, the Corporation hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in New York County, New York, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein (i) shall be deemed or operate to preclude any Holder from bringing suit or taking other legal action against the Corporation in any other jurisdiction to collect on the Corporation’s obligations to such Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of such Holder or (ii) shall limit, or shall be deemed or construed to limit, any provision of Section 22. The Corporation hereby irrevocably waives any right it may have to, and agrees not to request, a jury trial for the adjudication of any dispute hereunder or in connection with or arising out of this Certificate of Designations or any transaction contemplated hereby.
  
 25. Severability. If any provision of this Certificate of Designations is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Certificate of Designations so long as this Certificate of Designations as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).
  
 26. Amendment. This Certificate of Designations or any provision hereof (other than Section 5(d)) may be modified or amended or the provisions hereof waived with the written consent of the Corporation and either (i) the Holders of a majority of the Series B currently outstanding, which must include Cavalry as long as Cavalry (or any of its Affiliates) owns at least 5% of the Series B issued pursuant to the Exchange Agreement, or (ii) Cavalry as long as Cavalry (or any of its Affiliates) owns at least 5% of the Series B issued pursuant to the Exchange Agreement. No consideration (other than reimbursement of legal fees) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Exchange Agreement unless the same consideration also is offered to all of the parties to the Transaction Documents. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.
  
 	 
	40
	

	 

  
 27. Disclosure. Upon receipt or delivery by the Corporation of any notice in accordance with the terms of this Certificate of Designations, unless the Corporation has in good faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Corporation or any of its Subsidiaries, the Corporation shall within one Business Day after any such receipt or delivery publicly disclose such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Corporation believes that a notice contains material, non-public information relating to the Corporation or any of its Subsidiaries, the Corporation so shall indicate to such Holder contemporaneously with delivery of such notice, and in the absence of any such indication, such Holder shall be allowed to presume that all matters relating to such notice do not constitute material, non-public information relating to the Corporation or any of its Subsidiaries. If the Corporation or any of its Subsidiaries provides material non-public information to a Holder that is not simultaneously filed in a Current Report on Form 8-K and such Holder has not agreed to receive such material non-public information, the Corporation hereby covenants and agrees that such Holder shall not have any duty of confidentiality to the Corporation, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material non-public information. Nothing contained in this Section 27 shall limit any obligations of the Corporation, or any rights of any Holder, under the Exchange Agreement.
  
 * * * * *
   
 	 
	41
	

	 

    
 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Designations of Series B Convertible Preferred Stock of Gridiron BioNutrients, Inc. to be signed by its Chief Executive Officer on this 9th day of April , 2021.
    
 	  
	 GRIDIRON BIONUTRIENTS, INC.

	  
	  
	  
	 
	  
	 By:
	  
	 
	  
		 Timothy S. Orr, 
	 
	  
	  
	 Chief Executive Officer
	  

   
 	 
	42
	

	 

    
 EXHIBIT I
  
 GRIDIRON NUTRIENTS, INC.
 CONVERSION NOTICE
  
 Reference is made to the Certificate of Designations, Preferences and Rights of the Series B Convertible Preferred Stock of Gridiron Nutrients, Inc. (the “Certificate of Designations”). In accordance with and pursuant to the Certificate of Designations, the undersigned hereby elects to convert the number of shares of Series B Convertible Preferred Stock, $0.001 par value per share (the “Series B”), of Gridiron Nutrients, Inc., a Nevada corporation (the “Corporation”), indicated below into shares of common stock, $0.001 par value per share (the “Common Stock”), of the Corporation, as of the date specified below.
  
 	 Date of Conversion:
	  

	  
 Aggregate number of Series B to be converted
	  

	  
 Aggregate Stated Value of such Series B to be converted:
	  

	  
 Aggregate accrued and unpaid dividends and accrued and unpaid Late Charges with respect to such Series B
 and such aggregate dividends to be converted:
	  

	  
 AGGREGATE CONVERSION AMOUNT TO BE CONVERTED:
	  

	  
 Please confirm the following information:
	
	 Conversion Price:
	  

	 Number of shares of Common Stock to be issued:
	  

	  
 Please issue the Common Stock into which the applicable Series B are being converted to Holder, or for its benefit, as follows:
  
 ☐    Check here if requesting delivery as a certificate to the following name and to the following address:
	
	 Issue to:
	  

	  
	  

	  
	  

	 ☐    Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:
	
	 DTC Participant:
	  

	 DTC Number:
	  

	 Account Number:
	  

    
 	 
	43
	

	 

   
 Date: ______________________, ___
  
 Name of Registered Holder: __________________________________
 By:_______________________________________
 Name: ____________________________________
 Title: _____________________________________
 Tax ID: ___________________________________
 Facsimile:_________________________________
 E-mail Address: ____________________________
   
 	 
	44
	

	 

   
 EXHIBIT II
  
 ACKNOWLEDGMENT
  
 The Corporation hereby acknowledges this Conversion Notice and hereby directs _________________ to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated _____________, 20__ from the Corporation and acknowledged and agreed to by ________________________.
   
 	 	 GRIDIRON BIONUTRIENTS, INC.
	
	 	 	 	 
		By:		
	  
	 Name:
		 
	 	Title:		 

   
 	 
	45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]